Global Spatial OMICS Market By Techniques, By Offerings, By Application, By Sample Type, By End Users, By Region, Segmental Insights (2015 – 2031)

  • Industry: Healthcare
  • Report ID: TNR-1104-977
  • Number of Pages: 420
  • Table/Charts : Yes
  • November, 2023
  • Base Year : 2024
  • No. of Companies : 10+
  • No. of Countries : 29
  • Views : 10072
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

TNR States, Global Spatial OMICS Market was Valued USD 263.4 Mn in 2022, with an Estimated CAGR of 11.3% by 2031.

Spatial OMICS is a collective term for many technologies that allow OMICS data to be superimposed on tissue pictures. These approaches, in addition to identifying molecular subpopulations of cells, offer knowledge on the spatial localization of the identified subpopulations within the tissue of origin. Furthermore it analyzes their proximity to each other and the extracellular matrix, blood vessels, and other tissue components.

Genomics, for example, examines the entire genome, whereas transcriptomics reads the entire RNA and proteomics examines the protein composition. Spatial OMICS now integrates molecular analysis with geographical information on the location of cells inside tissues. As a result, this technology provides a strong tool for understanding critical systems such as tissue organisation and cell control.

Global Spatial OMICS Market Revenue & Forecast, (US$ Million), 2015 – 2031


Global Spatial OMICS Market Future

Significant advancements in next-generation sequencing and imaging-based methods have resulted in a revolution in the capacity to assess gene expression in tissue slices while maintaining cellular organization. When paired with single-cell RNA-seq, spatial OMICS techniques give a precise picture of cellular heterogeneity and tissue organisation. Moreover spatial OMICS is expected to become more widely adopted across various research areas, including cancer biology, neuroscience, and developmental biology, immunology, and drug discovery.  Its integration into clinical diagnostics and personalized medicine is a significant future prospect. Spatially resolved molecular profiling could aid in disease diagnosis, treatment selection, and monitoring patient responses to therapies leading to the growth of spatial OMICS market.

Report Coverage and Deliverables

Common

Spatial transcriptomics is a method that integrates gene expression studies with geographical context of cells. The spatial organisation of cell populations can be determined by mapping gene expression across tissue. Current spatial transcriptomic techniques, on the other hand, lack genuine single-cell resolution, depending on region of interest (ROI) or spot-based capture methods that cannot capture cellular variety properly. Nonetheless, transcriptomics is a potent research tool for discovery. The ability to profile hundreds of thousands of cells and thousands of genes in a single experiment allows for unbiased investigation of the tissue microenvironment, making this method extremely complimentary to imaging-based spatial proteomics.

Spatial genomics, in particular, has shown to be a vital instrument in disease research. Despite the fact that all human cells have the same genetic information, it is arranged and packed differently. This can influence which genes in each cell are translated into proteins. For example, spatial genomics may be used to isolate genetic variation in non-coding portions of the genome that causes a cell to become malignant. Furthermore, as the costs of DNA sequencing and lab automation fall, spatial genomics is gaining traction, with major centres including the United States, the United Kingdom, and Sweden.

Spatial OMICS market in North America, particularly in the United States and Canada, has seen significant growth and innovation in recent years. Leading universities and research institutions in North America are actively engaged in spatial OMICS research. They conduct studies across various fields, including cancer biology, neuroscience, developmental biology, and immunology, using spatial OMICS techniques to gain insights into complex biological processes. Major pharmaceutical and biotechnology companies based in North America are integrating spatial OMICS into their drug discovery and development pipelines. This includes applications in target identification, biomarker discovery, and assessing drug effects at the cellular level.

Competitive Landscape

The competitive landscape of spatial OMICS market is marked by innovation, collaboration, and rapid developments in technology and data analysis tools. Startups are contributing to the introduction of novel techniques and platforms, while established players are expanding their portfolios. Academic institutions and collaborative initiatives are fostering knowledge exchange and interdisciplinary research, further propelling the field’s advancement. As the spatial OMICS market continues to evolve, new entrants and developments are expected to shape its landscape further.

Major players operating in the global spatial OMICS market are:  

  • 10x Genomics
  • Agilent Technologies Inc
  • Akoya Biosciences
  • Bio-Techne
  • CD Genomics
  • Ilumina Inc
  • Indica Labs, Inc.
  • Miltenyi Biotec
  • NanoString Technologies Inc
  • Owkin
  • RareCyte, Inc.
  • S2 Genomics, Inc.
  • SciLifeLab
  • Ultivue Inc.
  • Visiopharm A/S
  • ZEISS
  • Other Industry Participants

Global Spatial OMICS Market Report Coverage

Report Specifications Details
Market Revenue in 2022 US$ 263.4 Million
Market Size Forecast by 2031 US$ 566.1 Million
Growth Rate (CAGR) 11.2%
Historic Data 2015 – 2021
Base Year for Estimation 2022
Forecast Period 2023 – 2031
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Techniques, By Offerings , By Application, By Sample Type, By End Users
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players 10x Genomics, Agilent Technologies Inc, Akoya Biosciences, Bio-Techne, CD Genomics, Ilumina Inc, Indica Labs, Inc., Miltenyi Biotec, NanoString Technologies Inc, Owkin, RareCyte, Inc., S2 Genomics, Inc., SciLifeLab, Ultivue Inc., Visiopharm A/S, ZEISS, Other Industry Participants
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808-703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

 

 

Global Spatial OMICS Market

By Techniques

  • Spatial Transcriptomics
    • Immunohistochemistry (IHC)
    • Fluorescence In-Situ Hybridization (FISH)
    • Sequencing
      • In Situ Sequencing (ISS)
      • Microdissection Sequencing
      • Others
    • In-Situ capturing
    • Microscopy based RNA imaging techniques
      • Padlock Probes & Rolling Circle Amplification
      • Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
      • Branched DNA probes
    • Transcriptome In-Vivo Analysis (TIVA)
  • Spatial Genomics
    • Fluorescence in situ Sequencing
    • Fluorescence Microscopy-based
    • Others
  • Spatial proteomics
  • Spatial metabolomics
  • Spatial multi-omics
  • Others

By Offerings

  • Products
  • Solutions
  • Consumables

By Application

  • Biomarker Discovery
  • Drug Development
  • Cancer Research
  • Infectious Diseases
  • Immunology
  • Metabolic Studies
  • Others

By Sample Type

  • Frozen tissues
  • FFPE tissues

By End Users

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

 

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2015 – 2021
1.2.2.Base Year: 2022
1.2.3.Forecast Years: 2023 – 2031
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from TNR’s Perspective**
5.Holistic Overview of Spatial OMICS Market
6.Market Synopsis: Spatial OMICS Market
7.Spatial OMICS Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.3.Trends in Spatial OMICS Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: Spatial OMICS Market
7.6.Porter’s Five Force Analysis
8.Global Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
8.1.Overview
8.1.1.Global Spatial OMICS Market Revenue (US$ Mn)
8.2.Global Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
8.2.1.Spatial Transcriptomics (Definition, Market Estimation and Penetration, 2015 – 2022, Market Estimation (2015 – 2022), Market Forecast (2023 – 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), Sequencing , In-Situ capturing , Microscopy based RNA imaging techniques , Transcriptome In-Vivo Analysis (TIVA))
8.2.1.1.Immunohistochemistry (IHC)
8.2.1.2.Fluorescence In-Situ Hybridization (FISH)
8.2.1.3.Sequencing
8.2.1.3.1.In Situ Sequencing (ISS)
8.2.1.3.2.Microdissection Sequencing
8.2.1.3.3.Others
8.2.1.4.In-Situ capturing
8.2.1.5.Microscopy based RNA imaging techniques
8.2.1.5.1.Padlock Probes and Rolling Circle Amplification
8.2.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
8.2.1.5.3.Branched DNA probes
8.2.1.6.Transcriptome In-Vivo Analysis (TIVA)
8.2.2.Spatial Genomics (Definition, Market Estimation and Penetration, 2015 – 2022, Market Estimation (2015 – 2022), Market Forecast (2023 – 2031), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Fluorescence in situ Sequencing, Fluorescence Microscopy-based , Others )
8.2.2.1.Fluorescence in situ Sequencing
8.2.2.2.Fluorescence Microscopy-based
8.2.2.3.Others
8.2.3.Spatial proteomics
8.2.3.1.Definition
8.2.3.2.Market Estimation and Penetration, 2015 – 2022
8.2.3.3.Market Forecast, 2023 – 2031
8.2.3.4.Compound Annual Growth Rate (CAGR)
8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2015 – 2022
8.2.3.5.1.2.Market Forecast, 2023 – 2031
8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2015 – 2022
8.2.3.5.2.2.Market Forecast, 2023 – 2031
8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2015 – 2022
8.2.3.5.3.2.Market Forecast, 2023 – 2031
8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2015 – 2022
8.2.3.5.4.2.Market Forecast, 2023 – 2031
8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2015 – 2022
8.2.3.5.5.2.Market Forecast, 2023 – 2031
8.2.4.Spatial metabolomics
8.2.4.1.Definition
8.2.4.2.Market Estimation and Penetration, 2015 – 2022
8.2.4.3.Market Forecast, 2023 – 2031
8.2.4.4.Compound Annual Growth Rate (CAGR)
8.2.4.5.Regional Bifurcation
8.2.4.5.1.North America
8.2.4.5.1.1.Market Estimation, 2015 – 2022
8.2.4.5.1.2.Market Forecast, 2023 – 2031
8.2.4.5.2.Europe
8.2.4.5.2.1.Market Estimation, 2015 – 2022
8.2.4.5.2.2.Market Forecast, 2023 – 2031
8.2.4.5.3.Asia Pacific
8.2.4.5.3.1.Market Estimation, 2015 – 2022
8.2.4.5.3.2.Market Forecast, 2023 – 2031
8.2.4.5.4.Middle East and Africa
8.2.4.5.4.1.Market Estimation, 2015 – 2022
8.2.4.5.4.2.Market Forecast, 2023 – 2031
8.2.4.5.5.Latin America
8.2.4.5.5.1.Market Estimation, 2015 – 2022
8.2.4.5.5.2.Market Forecast, 2023 – 2031
8.2.5.Spatial multi-omics
8.2.5.1.Definition
8.2.5.2.Market Estimation and Penetration, 2015 – 2022
8.2.5.3.Market Forecast, 2023 – 2031
8.2.5.4.Compound Annual Growth Rate (CAGR)
8.2.5.5.Regional Bifurcation
8.2.5.5.1.North America
8.2.5.5.1.1.Market Estimation, 2015 – 2022
8.2.5.5.1.2.Market Forecast, 2023 – 2031
8.2.5.5.2.Europe
8.2.5.5.2.1.Market Estimation, 2015 – 2022
8.2.5.5.2.2.Market Forecast, 2023 – 2031
8.2.5.5.3.Asia Pacific
8.2.5.5.3.1.Market Estimation, 2015 – 2022
8.2.5.5.3.2.Market Forecast, 2023 – 2031
8.2.5.5.4.Middle East and Africa
8.2.5.5.4.1.Market Estimation, 2015 – 2022
8.2.5.5.4.2.Market Forecast, 2023 – 2031
8.2.5.5.5.Latin America
8.2.5.5.5.1.Market Estimation, 2015 – 2022
8.2.5.5.5.2.Market Forecast, 2023 – 2031
8.2.6.Others
8.2.6.1.Definition
8.2.6.2.Market Estimation and Penetration, 2015 – 2022
8.2.6.3.Market Forecast, 2023 – 2031
8.2.6.4.Compound Annual Growth Rate (CAGR)
8.2.6.5.Regional Bifurcation
8.2.6.5.1.North America
8.2.6.5.1.1.Market Estimation, 2015 – 2022
8.2.6.5.1.2.Market Forecast, 2023 – 2031
8.2.6.5.2.Europe
8.2.6.5.2.1.Market Estimation, 2015 – 2022
8.2.6.5.2.2.Market Forecast, 2023 – 2031
8.2.6.5.3.Asia Pacific
8.2.6.5.3.1.Market Estimation, 2015 – 2022
8.2.6.5.3.2.Market Forecast, 2023 – 2031
8.2.6.5.4.Middle East and Africa
8.2.6.5.4.1.Market Estimation, 2015 – 2022
8.2.6.5.4.2.Market Forecast, 2023 – 2031
8.2.6.5.5.Latin America
8.2.6.5.5.1.Market Estimation, 2015 – 2022
8.2.6.5.5.2.Market Forecast, 2023 – 2031
8.3.Key Segment for Channeling Investments
8.3.1.By Techniques
9.Global Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
9.1.Overview
9.2.Global Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
9.2.1.Products
9.2.1.1.Definition
9.2.1.2.Market Estimation and Penetration, 2015 – 2022
9.2.1.3.Market Forecast, 2023 – 2031
9.2.1.4.Compound Annual Growth Rate (CAGR)
9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2015 – 2022
9.2.1.5.1.2.Market Forecast, 2023 – 2031
9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2015 – 2022
9.2.1.5.2.2.Market Forecast, 2023 – 2031
9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2015 – 2022
9.2.1.5.3.2.Market Forecast, 2023 – 2031
9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2015 – 2022
9.2.1.5.4.2.Market Forecast, 2023 – 2031
9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2015 – 2022
9.2.1.5.5.2.Market Forecast, 2023 – 2031
9.2.2.Solutions
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2015 – 2022
9.2.2.3.Market Forecast, 2023 – 2031
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2015 – 2022
9.2.2.5.1.2.Market Forecast, 2023 – 2031
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2015 – 2022
9.2.2.5.2.2.Market Forecast, 2023 – 2031
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2015 – 2022
9.2.2.5.3.2.Market Forecast, 2023 – 2031
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2015 – 2022
9.2.2.5.4.2.Market Forecast, 2023 – 2031
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2015 – 2022
9.2.2.5.5.2.Market Forecast, 2023 – 2031
9.2.3.Consumables
9.2.3.1.Definition
9.2.3.2.Market Estimation and Penetration, 2015 – 2022
9.2.3.3.Market Forecast, 2023 – 2031
9.2.3.4.Compound Annual Growth Rate (CAGR)
9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2015 – 2022
9.2.3.5.1.2.Market Forecast, 2023 – 2031
9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2015 – 2022
9.2.3.5.2.2.Market Forecast, 2023 – 2031
9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2015 – 2022
9.2.3.5.3.2.Market Forecast, 2023 – 2031
9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2015 – 2022
9.2.3.5.4.2.Market Forecast, 2023 – 2031
9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2015 – 2022
9.2.3.5.5.2.Market Forecast, 2023 – 2031
9.3.Key Segment for Channeling Investments
9.3.1.By Offerings
10.Global Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
10.1.Overview
10.2.Global Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
10.2.1.Biomarker Discovery
10.2.1.1.Definition
10.2.1.2.Market Estimation and Penetration, 2015 – 2022
10.2.1.3.Market Forecast, 2023 – 2031
10.2.1.4.Compound Annual Growth Rate (CAGR)
10.2.1.5.Regional Bifurcation
10.2.1.5.1.North America
10.2.1.5.1.1.Market Estimation, 2015 – 2022
10.2.1.5.1.2.Market Forecast, 2023 – 2031
10.2.1.5.2.Europe
10.2.1.5.2.1.Market Estimation, 2015 – 2022
10.2.1.5.2.2.Market Forecast, 2023 – 2031
10.2.1.5.3.Asia Pacific
10.2.1.5.3.1.Market Estimation, 2015 – 2022
10.2.1.5.3.2.Market Forecast, 2023 – 2031
10.2.1.5.4.Middle East and Africa
10.2.1.5.4.1.Market Estimation, 2015 – 2022
10.2.1.5.4.2.Market Forecast, 2023 – 2031
10.2.1.5.5.Latin America
10.2.1.5.5.1.Market Estimation, 2015 – 2022
10.2.1.5.5.2.Market Forecast, 2023 – 2031
10.2.2.Drug Development
10.2.2.1.Definition
10.2.2.2.Market Estimation and Penetration, 2015 – 2022
10.2.2.3.Market Forecast, 2023 – 2031
10.2.2.4.Compound Annual Growth Rate (CAGR)
10.2.2.5.Regional Bifurcation
10.2.2.5.1.North America
10.2.2.5.1.1.Market Estimation, 2015 – 2022
10.2.2.5.1.2.Market Forecast, 2023 – 2031
10.2.2.5.2.Europe
10.2.2.5.2.1.Market Estimation, 2015 – 2022
10.2.2.5.2.2.Market Forecast, 2023 – 2031
10.2.2.5.3.Asia Pacific
10.2.2.5.3.1.Market Estimation, 2015 – 2022
10.2.2.5.3.2.Market Forecast, 2023 – 2031
10.2.2.5.4.Middle East and Africa
10.2.2.5.4.1.Market Estimation, 2015 – 2022
10.2.2.5.4.2.Market Forecast, 2023 – 2031
10.2.2.5.5.Latin America
10.2.2.5.5.1.Market Estimation, 2015 – 2022
10.2.2.5.5.2.Market Forecast, 2023 – 2031
10.2.3.Cancer Research
10.2.3.1.Definition
10.2.3.2.Market Estimation and Penetration, 2015 – 2022
10.2.3.3.Market Forecast, 2023 – 2031
10.2.3.4.Compound Annual Growth Rate (CAGR)
10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2015 – 2022
10.2.3.5.1.2.Market Forecast, 2023 – 2031
10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2015 – 2022
10.2.3.5.2.2.Market Forecast, 2023 – 2031
10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2015 – 2022
10.2.3.5.3.2.Market Forecast, 2023 – 2031
10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2015 – 2022
10.2.3.5.4.2.Market Forecast, 2023 – 2031
10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2015 – 2022
10.2.3.5.5.2.Market Forecast, 2023 – 2031
10.2.4.Infectious Diseases
10.2.4.1.Definition
10.2.4.2.Market Estimation and Penetration, 2015 – 2022
10.2.4.3.Market Forecast, 2023 – 2031
10.2.4.4.Compound Annual Growth Rate (CAGR)
10.2.4.5.Regional Bifurcation
10.2.4.5.1.North America
10.2.4.5.1.1.Market Estimation, 2015 – 2022
10.2.4.5.1.2.Market Forecast, 2023 – 2031
10.2.4.5.2.Europe
10.2.4.5.2.1.Market Estimation, 2015 – 2022
10.2.4.5.2.2.Market Forecast, 2023 – 2031
10.2.4.5.3.Asia Pacific
10.2.4.5.3.1.Market Estimation, 2015 – 2022
10.2.4.5.3.2.Market Forecast, 2023 – 2031
10.2.4.5.4.Middle East and Africa
10.2.4.5.4.1.Market Estimation, 2015 – 2022
10.2.4.5.4.2.Market Forecast, 2023 – 2031
10.2.4.5.5.Latin America
10.2.4.5.5.1.Market Estimation, 2015 – 2022
10.2.4.5.5.2.Market Forecast, 2023 – 2031
10.2.5.Immunology
10.2.5.1.Definition
10.2.5.2.Market Estimation and Penetration, 2015 – 2022
10.2.5.3.Market Forecast, 2023 – 2031
10.2.5.4.Compound Annual Growth Rate (CAGR)
10.2.5.5.Regional Bifurcation
10.2.5.5.1.North America
10.2.5.5.1.1.Market Estimation, 2015 – 2022
10.2.5.5.1.2.Market Forecast, 2023 – 2031
10.2.5.5.2.Europe
10.2.5.5.2.1.Market Estimation, 2015 – 2022
10.2.5.5.2.2.Market Forecast, 2023 – 2031
10.2.5.5.3.Asia Pacific
10.2.5.5.3.1.Market Estimation, 2015 – 2022
10.2.5.5.3.2.Market Forecast, 2023 – 2031
10.2.5.5.4.Middle East and Africa
10.2.5.5.4.1.Market Estimation, 2015 – 2022
10.2.5.5.4.2.Market Forecast, 2023 – 2031
10.2.5.5.5.Latin America
10.2.5.5.5.1.Market Estimation, 2015 – 2022
10.2.5.5.5.2.Market Forecast, 2023 – 2031
10.2.6.Metabolic Studies
10.2.6.1.Definition
10.2.6.2.Market Estimation and Penetration, 2015 – 2022
10.2.6.3.Market Forecast, 2023 – 2031
10.2.6.4.Compound Annual Growth Rate (CAGR)
10.2.6.5.Regional Bifurcation
10.2.6.5.1.North America
10.2.6.5.1.1.Market Estimation, 2015 – 2022
10.2.6.5.1.2.Market Forecast, 2023 – 2031
10.2.6.5.2.Europe
10.2.6.5.2.1.Market Estimation, 2015 – 2022
10.2.6.5.2.2.Market Forecast, 2023 – 2031
10.2.6.5.3.Asia Pacific
10.2.6.5.3.1.Market Estimation, 2015 – 2022
10.2.6.5.3.2.Market Forecast, 2023 – 2031
10.2.6.5.4.Middle East and Africa
10.2.6.5.4.1.Market Estimation, 2015 – 2022
10.2.6.5.4.2.Market Forecast, 2023 – 2031
10.2.6.5.5.Latin America
10.2.6.5.5.1.Market Estimation, 2015 – 2022
10.2.6.5.5.2.Market Forecast, 2023 – 2031
10.2.7.Others
10.2.7.1.Definition
10.2.7.2.Market Estimation and Penetration, 2015 – 2022
10.2.7.3.Market Forecast, 2023 – 2031
10.2.7.4.Compound Annual Growth Rate (CAGR)
10.2.7.5.Regional Bifurcation
10.2.7.5.1.North America
10.2.7.5.1.1.Market Estimation, 2015 – 2022
10.2.7.5.1.2.Market Forecast, 2023 – 2031
10.2.7.5.2.Europe
10.2.7.5.2.1.Market Estimation, 2015 – 2022
10.2.7.5.2.2.Market Forecast, 2023 – 2031
10.2.7.5.3.Asia Pacific
10.2.7.5.3.1.Market Estimation, 2015 – 2022
10.2.7.5.3.2.Market Forecast, 2023 – 2031
10.2.7.5.4.Middle East and Africa
10.2.7.5.4.1.Market Estimation, 2015 – 2022
10.2.7.5.4.2.Market Forecast, 2023 – 2031
10.2.7.5.5.Latin America
10.2.7.5.5.1.Market Estimation, 2015 – 2022
10.2.7.5.5.2.Market Forecast, 2023 – 2031
10.3.Key Segment for Channeling Investments
10.3.1.By Application
11.Global Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
11.1.Overview
11.2.Global Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
11.2.1.Frozen tissues
11.2.1.1.Definition
11.2.1.2.Market Estimation and Penetration, 2015 – 2022
11.2.1.3.Market Forecast, 2023 – 2031
11.2.1.4.Compound Annual Growth Rate (CAGR)
11.2.1.5.Regional Bifurcation
11.2.1.5.1.North America
11.2.1.5.1.1.Market Estimation, 2015 – 2022
11.2.1.5.1.2.Market Forecast, 2023 – 2031
11.2.1.5.2.Europe
11.2.1.5.2.1.Market Estimation, 2015 – 2022
11.2.1.5.2.2.Market Forecast, 2023 – 2031
11.2.1.5.3.Asia Pacific
11.2.1.5.3.1.Market Estimation, 2015 – 2022
11.2.1.5.3.2.Market Forecast, 2023 – 2031
11.2.1.5.4.Middle East and Africa
11.2.1.5.4.1.Market Estimation, 2015 – 2022
11.2.1.5.4.2.Market Forecast, 2023 – 2031
11.2.1.5.5.Latin America
11.2.1.5.5.1.Market Estimation, 2015 – 2022
11.2.1.5.5.2.Market Forecast, 2023 – 2031
11.2.2.FFPE tissues
11.2.2.1.Definition
11.2.2.2.Market Estimation and Penetration, 2015 – 2022
11.2.2.3.Market Forecast, 2023 – 2031
11.2.2.4.Compound Annual Growth Rate (CAGR)
11.2.2.5.Regional Bifurcation
11.2.2.5.1.North America
11.2.2.5.1.1.Market Estimation, 2015 – 2022
11.2.2.5.1.2.Market Forecast, 2023 – 2031
11.2.2.5.2.Europe
11.2.2.5.2.1.Market Estimation, 2015 – 2022
11.2.2.5.2.2.Market Forecast, 2023 – 2031
11.2.2.5.3.Asia Pacific
11.2.2.5.3.1.Market Estimation, 2015 – 2022
11.2.2.5.3.2.Market Forecast, 2023 – 2031
11.2.2.5.4.Middle East and Africa
11.2.2.5.4.1.Market Estimation, 2015 – 2022
11.2.2.5.4.2.Market Forecast, 2023 – 2031
11.2.2.5.5.Latin America
11.2.2.5.5.1.Market Estimation, 2015 – 2022
11.2.2.5.5.2.Market Forecast, 2023 – 2031
11.3.Key Segment for Channeling Investments
11.3.1.By Sample Type
12.Global Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
12.1.Overview
12.2.Global Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
12.2.1.Academic and Research Institutes
12.2.1.1.Definition
12.2.1.2.Market Estimation and Penetration, 2015 – 2022
12.2.1.3.Market Forecast, 2023 – 2031
12.2.1.4.Compound Annual Growth Rate (CAGR)
12.2.1.5.Regional Bifurcation
12.2.1.5.1.North America
12.2.1.5.1.1.Market Estimation, 2015 – 2022
12.2.1.5.1.2.Market Forecast, 2023 – 2031
12.2.1.5.2.Europe
12.2.1.5.2.1.Market Estimation, 2015 – 2022
12.2.1.5.2.2.Market Forecast, 2023 – 2031
12.2.1.5.3.Asia Pacific
12.2.1.5.3.1.Market Estimation, 2015 – 2022
12.2.1.5.3.2.Market Forecast, 2023 – 2031
12.2.1.5.4.Middle East and Africa
12.2.1.5.4.1.Market Estimation, 2015 – 2022
12.2.1.5.4.2.Market Forecast, 2023 – 2031
12.2.1.5.5.Latin America
12.2.1.5.5.1.Market Estimation, 2015 – 2022
12.2.1.5.5.2.Market Forecast, 2023 – 2031
12.2.2.Pharmaceutical and Biotechnology Companies
12.2.2.1.Definition
12.2.2.2.Market Estimation and Penetration, 2015 – 2022
12.2.2.3.Market Forecast, 2023 – 2031
12.2.2.4.Compound Annual Growth Rate (CAGR)
12.2.2.5.Regional Bifurcation
12.2.2.5.1.North America
12.2.2.5.1.1.Market Estimation, 2015 – 2022
12.2.2.5.1.2.Market Forecast, 2023 – 2031
12.2.2.5.2.Europe
12.2.2.5.2.1.Market Estimation, 2015 – 2022
12.2.2.5.2.2.Market Forecast, 2023 – 2031
12.2.2.5.3.Asia Pacific
12.2.2.5.3.1.Market Estimation, 2015 – 2022
12.2.2.5.3.2.Market Forecast, 2023 – 2031
12.2.2.5.4.Middle East and Africa
12.2.2.5.4.1.Market Estimation, 2015 – 2022
12.2.2.5.4.2.Market Forecast, 2023 – 2031
12.2.2.5.5.Latin America
12.2.2.5.5.1.Market Estimation, 2015 – 2022
12.2.2.5.5.2.Market Forecast, 2023 – 2031
12.2.3.Contract Research Organizations (CROs)
12.2.3.1.Definition
12.2.3.2.Market Estimation and Penetration, 2015 – 2022
12.2.3.3.Market Forecast, 2023 – 2031
12.2.3.4.Compound Annual Growth Rate (CAGR)
12.2.3.5.Regional Bifurcation
12.2.3.5.1.North America
12.2.3.5.1.1.Market Estimation, 2015 – 2022
12.2.3.5.1.2.Market Forecast, 2023 – 2031
12.2.3.5.2.Europe
12.2.3.5.2.1.Market Estimation, 2015 – 2022
12.2.3.5.2.2.Market Forecast, 2023 – 2031
12.2.3.5.3.Asia Pacific
12.2.3.5.3.1.Market Estimation, 2015 – 2022
12.2.3.5.3.2.Market Forecast, 2023 – 2031
12.2.3.5.4.Middle East and Africa
12.2.3.5.4.1.Market Estimation, 2015 – 2022
12.2.3.5.4.2.Market Forecast, 2023 – 2031
12.2.3.5.5.Latin America
12.2.3.5.5.1.Market Estimation, 2015 – 2022
12.2.3.5.5.2.Market Forecast, 2023 – 2031
12.2.4.Others
12.2.4.1.Definition
12.2.4.2.Market Estimation and Penetration, 2015 – 2022
12.2.4.3.Market Forecast, 2023 – 2031
12.2.4.4.Compound Annual Growth Rate (CAGR)
12.2.4.5.Regional Bifurcation
12.2.4.5.1.North America
12.2.4.5.1.1.Market Estimation, 2015 – 2022
12.2.4.5.1.2.Market Forecast, 2023 – 2031
12.2.4.5.2.Europe
12.2.4.5.2.1.Market Estimation, 2015 – 2022
12.2.4.5.2.2.Market Forecast, 2023 – 2031
12.2.4.5.3.Asia Pacific
12.2.4.5.3.1.Market Estimation, 2015 – 2022
12.2.4.5.3.2.Market Forecast, 2023 – 2031
12.2.4.5.4.Middle East and Africa
12.2.4.5.4.1.Market Estimation, 2015 – 2022
12.2.4.5.4.2.Market Forecast, 2023 – 2031
12.2.4.5.5.Latin America
12.2.4.5.5.1.Market Estimation, 2015 – 2022
12.2.4.5.5.2.Market Forecast, 2023 – 2031
12.3.Key Segment for Channeling Investments
12.3.1.By End Users
13.North America Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
13.1.Overview
13.1.1.North America Spatial OMICS Market Revenue (US$ Mn)
13.2.North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
13.2.1.Spatial Transcriptomics
13.2.1.1.Immunohistochemistry (IHC)
13.2.1.2.Fluorescence In-Situ Hybridization (FISH)
13.2.1.3.Sequencing
13.2.1.3.1.In Situ Sequencing (ISS)
13.2.1.3.2.Microdissection Sequencing
13.2.1.3.3.Others
13.2.1.4.In-Situ capturing
13.2.1.5.Microscopy based RNA imaging techniques
13.2.1.5.1.Padlock Probes and Rolling Circle Amplification
13.2.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
13.2.1.5.3.Branched DNA probes
13.2.1.6.Transcriptome In-Vivo Analysis (TIVA)
13.2.2.Spatial Genomics
13.2.2.1.Fluorescence in situ Sequencing
13.2.2.2.Fluorescence Microscopy-based
13.2.2.3.Others
13.2.3.Spatial proteomics
13.2.4.Spatial metabolomics
13.2.5.Spatial multi-omics
13.2.6.Others
13.3.North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
13.3.1.Products
13.3.2.Solutions
13.3.3.Consumables
13.4.North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
13.4.1.Biomarker Discovery
13.4.2.Drug Development
13.4.3.Cancer Research
13.4.4.Infectious Diseases
13.4.5.Immunology
13.4.6.Metabolic Studies
13.4.7.Others
13.5.North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
13.5.1.Frozen tissues
13.5.2.FFPE tissues
13.6.North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.Academic and Research Institutes
13.6.2.Pharmaceutical and Biotechnology Companies
13.6.3.Contract Research Organizations (CROs)
13.6.4.Others
13.7.North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1.U.S
13.7.1.1.U.S Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
13.7.1.1.1.Spatial Transcriptomics
13.7.1.1.1.1.Immunohistochemistry (IHC)
13.7.1.1.1.2.Fluorescence In-Situ Hybridization (FISH)
13.7.1.1.1.3.Sequencing
13.7.1.1.1.3.1.In Situ Sequencing (ISS)
13.7.1.1.1.3.2.Microdissection Sequencing
13.7.1.1.1.3.3.Others
13.7.1.1.1.4.In-Situ capturing
13.7.1.1.1.5.Microscopy based RNA imaging techniques
13.7.1.1.1.5.1.Padlock Probes and Rolling Circle Amplification
13.7.1.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
13.7.1.1.1.5.3.Branched DNA probes
13.7.1.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
13.7.1.1.2.Spatial Genomics
13.7.1.1.2.1.Fluorescence in situ Sequencing
13.7.1.1.2.2.Fluorescence Microscopy-based
13.7.1.1.2.3.Others
13.7.1.1.3.Spatial proteomics
13.7.1.1.4.Spatial metabolomics
13.7.1.1.5.Spatial multi-omics
13.7.1.1.6.Others
13.7.1.2.U.S Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
13.7.1.2.1.Products
13.7.1.2.2.Solutions
13.7.1.2.3.Consumables
13.7.1.3.U.S Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
13.7.1.3.1.Biomarker Discovery
13.7.1.3.2.Drug Development
13.7.1.3.3.Cancer Research
13.7.1.3.4.Infectious Diseases
13.7.1.3.5.Immunology
13.7.1.3.6.Metabolic Studies
13.7.1.3.7.Others
13.7.1.4.U.S Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
13.7.1.4.1.Frozen tissues
13.7.1.4.2.FFPE tissues
13.7.1.5.U.S Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
13.7.1.5.1.Academic and Research Institutes
13.7.1.5.2.Pharmaceutical and Biotechnology Companies
13.7.1.5.3.Contract Research Organizations (CROs)
13.7.1.5.4.Others
13.7.2.Canada
13.7.2.1.Canada Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
13.7.2.1.1.Spatial Transcriptomics
13.7.2.1.1.1.Immunohistochemistry (IHC)
13.7.2.1.1.2.Fluorescence In-Situ Hybridization (FISH)
13.7.2.1.1.3.Sequencing
13.7.2.1.1.3.1.In Situ Sequencing (ISS)
13.7.2.1.1.3.2.Microdissection Sequencing
13.7.2.1.1.3.3.Others
13.7.2.1.1.4.In-Situ capturing
13.7.2.1.1.5.Microscopy based RNA imaging techniques
13.7.2.1.1.5.1.Padlock Probes and Rolling Circle Amplification
13.7.2.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
13.7.2.1.1.5.3.Branched DNA probes
13.7.2.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
13.7.2.1.2.Spatial Genomics
13.7.2.1.2.1.Fluorescence in situ Sequencing
13.7.2.1.2.2.Fluorescence Microscopy-based
13.7.2.1.2.3.Others
13.7.2.1.3.Spatial proteomics
13.7.2.1.4.Spatial metabolomics
13.7.2.1.5.Spatial multi-omics
13.7.2.1.6.Others
13.7.2.2.Canada Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
13.7.2.2.1.Products
13.7.2.2.2.Solutions
13.7.2.2.3.Consumables
13.7.2.3.Canada Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
13.7.2.3.1.Biomarker Discovery
13.7.2.3.2.Drug Development
13.7.2.3.3.Cancer Research
13.7.2.3.4.Infectious Diseases
13.7.2.3.5.Immunology
13.7.2.3.6.Metabolic Studies
13.7.2.3.7.Others
13.7.2.4.Canada Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
13.7.2.4.1.Frozen tissues
13.7.2.4.2.FFPE tissues
13.7.2.5.Canada Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
13.7.2.5.1.Academic and Research Institutes
13.7.2.5.2.Pharmaceutical and Biotechnology Companies
13.7.2.5.3.Contract Research Organizations (CROs)
13.7.2.5.4.Others
13.7.3.Mexico
13.7.3.1.Mexico Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
13.7.3.1.1.Spatial Transcriptomics
13.7.3.1.1.1.Immunohistochemistry (IHC)
13.7.3.1.1.2.Fluorescence In-Situ Hybridization (FISH)
13.7.3.1.1.3.Sequencing
13.7.3.1.1.3.1.In Situ Sequencing (ISS)
13.7.3.1.1.3.2.Microdissection Sequencing
13.7.3.1.1.3.3.Others
13.7.3.1.1.4.In-Situ capturing
13.7.3.1.1.5.Microscopy based RNA imaging techniques
13.7.3.1.1.5.1.Padlock Probes and Rolling Circle Amplification
13.7.3.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
13.7.3.1.1.5.3.Branched DNA probes
13.7.3.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
13.7.3.1.2.Spatial Genomics
13.7.3.1.2.1.Fluorescence in situ Sequencing
13.7.3.1.2.2.Fluorescence Microscopy-based
13.7.3.1.2.3.Others
13.7.3.1.3.Spatial proteomics
13.7.3.1.4.Spatial metabolomics
13.7.3.1.5.Spatial multi-omics
13.7.3.1.6.Others
13.7.3.2.Mexico Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
13.7.3.2.1.Products
13.7.3.2.2.Solutions
13.7.3.2.3.Consumables
13.7.3.3.Mexico Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
13.7.3.3.1.Biomarker Discovery
13.7.3.3.2.Drug Development
13.7.3.3.3.Cancer Research
13.7.3.3.4.Infectious Diseases
13.7.3.3.5.Immunology
13.7.3.3.6.Metabolic Studies
13.7.3.3.7.Others
13.7.3.4.Mexico Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
13.7.3.4.1.Frozen tissues
13.7.3.4.2.FFPE tissues
13.7.3.5.Mexico Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
13.7.3.5.1.Academic and Research Institutes
13.7.3.5.2.Pharmaceutical and Biotechnology Companies
13.7.3.5.3.Contract Research Organizations (CROs)
13.7.3.5.4.Others
13.7.4.Rest of North America
13.7.4.1.Rest of North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
13.7.4.1.1.Spatial Transcriptomics
13.7.4.1.1.1.Immunohistochemistry (IHC)
13.7.4.1.1.2.Fluorescence In-Situ Hybridization (FISH)
13.7.4.1.1.3.Sequencing
13.7.4.1.1.3.1.In Situ Sequencing (ISS)
13.7.4.1.1.3.2.Microdissection Sequencing
13.7.4.1.1.3.3.Others
13.7.4.1.1.4.In-Situ capturing
13.7.4.1.1.5.Microscopy based RNA imaging techniques
13.7.4.1.1.5.1.Padlock Probes and Rolling Circle Amplification
13.7.4.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
13.7.4.1.1.5.3.Branched DNA probes
13.7.4.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
13.7.4.1.2.Spatial Genomics
13.7.4.1.2.1.Fluorescence in situ Sequencing
13.7.4.1.2.2.Fluorescence Microscopy-based
13.7.4.1.2.3.Others
13.7.4.1.3.Spatial proteomics
13.7.4.1.4.Spatial metabolomics
13.7.4.1.5.Spatial multi-omics
13.7.4.1.6.Others
13.7.4.2.Rest of North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
13.7.4.2.1.Products
13.7.4.2.2.Solutions
13.7.4.2.3.Consumables
13.7.4.3.Rest of North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
13.7.4.3.1.Biomarker Discovery
13.7.4.3.2.Drug Development
13.7.4.3.3.Cancer Research
13.7.4.3.4.Infectious Diseases
13.7.4.3.5.Immunology
13.7.4.3.6.Metabolic Studies
13.7.4.3.7.Others
13.7.4.4.Rest of North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
13.7.4.4.1.Frozen tissues
13.7.4.4.2.FFPE tissues
13.7.4.5.Rest of North America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
13.7.4.5.1.Academic and Research Institutes
13.7.4.5.2.Pharmaceutical and Biotechnology Companies
13.7.4.5.3.Contract Research Organizations (CROs)
13.7.4.5.4.Others
13.8.Key Segment for Channeling Investments
13.8.1.By Country
13.8.2.By Techniques
13.8.3.By Offerings
13.8.4.By Application
13.8.5.By Sample Type
13.8.6.By End Users
14.Europe Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
14.1.Overview
14.1.1.Europe Spatial OMICS Market Revenue (US$ Mn)
14.2.Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
14.2.1.Spatial Transcriptomics
14.2.1.1.Immunohistochemistry (IHC)
14.2.1.2.Fluorescence In-Situ Hybridization (FISH)
14.2.1.3.Sequencing
14.2.1.3.1.In Situ Sequencing (ISS)
14.2.1.3.2.Microdissection Sequencing
14.2.1.3.3.Others
14.2.1.4.In-Situ capturing
14.2.1.5.Microscopy based RNA imaging techniques
14.2.1.5.1.Padlock Probes and Rolling Circle Amplification
14.2.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
14.2.1.5.3.Branched DNA probes
14.2.1.6.Transcriptome In-Vivo Analysis (TIVA)
14.2.2.Spatial Genomics
14.2.2.1.Fluorescence in situ Sequencing
14.2.2.2.Fluorescence Microscopy-based
14.2.2.3.Others
14.2.3.Spatial proteomics
14.2.4.Spatial metabolomics
14.2.5.Spatial multi-omics
14.2.6.Others
14.3.Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
14.3.1.Products
14.3.2.Solutions
14.3.3.Consumables
14.4.Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
14.4.1.Biomarker Discovery
14.4.2.Drug Development
14.4.3.Cancer Research
14.4.4.Infectious Diseases
14.4.5.Immunology
14.4.6.Metabolic Studies
14.4.7.Others
14.5.Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
14.5.1.Frozen tissues
14.5.2.FFPE tissues
14.6.Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
14.6.1.Academic and Research Institutes
14.6.2.Pharmaceutical and Biotechnology Companies
14.6.3.Contract Research Organizations (CROs)
14.6.4.Others
14.7.Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Country
14.7.1.France
14.7.1.1.France Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
14.7.1.1.1.Spatial Transcriptomics
14.7.1.1.1.1.Immunohistochemistry (IHC)
14.7.1.1.1.2.Fluorescence In-Situ Hybridization (FISH)
14.7.1.1.1.3.Sequencing
14.7.1.1.1.3.1.In Situ Sequencing (ISS)
14.7.1.1.1.3.2.Microdissection Sequencing
14.7.1.1.1.3.3.Others
14.7.1.1.1.4.In-Situ capturing
14.7.1.1.1.5.Microscopy based RNA imaging techniques
14.7.1.1.1.5.1.Padlock Probes and Rolling Circle Amplification
14.7.1.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
14.7.1.1.1.5.3.Branched DNA probes
14.7.1.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
14.7.1.1.2.Spatial Genomics
14.7.1.1.2.1.Fluorescence in situ Sequencing
14.7.1.1.2.2.Fluorescence Microscopy-based
14.7.1.1.2.3.Others
14.7.1.1.3.Spatial proteomics
14.7.1.1.4.Spatial metabolomics
14.7.1.1.5.Spatial multi-omics
14.7.1.1.6.Others
14.7.1.2.France Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
14.7.1.2.1.Products
14.7.1.2.2.Solutions
14.7.1.2.3.Consumables
14.7.1.3.France Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
14.7.1.3.1.Biomarker Discovery
14.7.1.3.2.Drug Development
14.7.1.3.3.Cancer Research
14.7.1.3.4.Infectious Diseases
14.7.1.3.5.Immunology
14.7.1.3.6.Metabolic Studies
14.7.1.3.7.Others
14.7.1.4.France Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
14.7.1.4.1.Frozen tissues
14.7.1.4.2.FFPE tissues
14.7.1.5.France Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.1.5.1.Academic and Research Institutes
14.7.1.5.2.Pharmaceutical and Biotechnology Companies
14.7.1.5.3.Contract Research Organizations (CROs)
14.7.1.5.4.Others
14.7.2.The UK
14.7.2.1.The UK Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
14.7.2.1.1.Spatial Transcriptomics
14.7.2.1.1.1.Immunohistochemistry (IHC)
14.7.2.1.1.2.Fluorescence In-Situ Hybridization (FISH)
14.7.2.1.1.3.Sequencing
14.7.2.1.1.3.1.In Situ Sequencing (ISS)
14.7.2.1.1.3.2.Microdissection Sequencing
14.7.2.1.1.3.3.Others
14.7.2.1.1.4.In-Situ capturing
14.7.2.1.1.5.Microscopy based RNA imaging techniques
14.7.2.1.1.5.1.Padlock Probes and Rolling Circle Amplification
14.7.2.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
14.7.2.1.1.5.3.Branched DNA probes
14.7.2.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
14.7.2.1.2.Spatial Genomics
14.7.2.1.2.1.Fluorescence in situ Sequencing
14.7.2.1.2.2.Fluorescence Microscopy-based
14.7.2.1.2.3.Others
14.7.2.1.3.Spatial proteomics
14.7.2.1.4.Spatial metabolomics
14.7.2.1.5.Spatial multi-omics
14.7.2.1.6.Others
14.7.2.2.The UK Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
14.7.2.2.1.Products
14.7.2.2.2.Solutions
14.7.2.2.3.Consumables
14.7.2.3.The UK Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
14.7.2.3.1.Biomarker Discovery
14.7.2.3.2.Drug Development
14.7.2.3.3.Cancer Research
14.7.2.3.4.Infectious Diseases
14.7.2.3.5.Immunology
14.7.2.3.6.Metabolic Studies
14.7.2.3.7.Others
14.7.2.4.The UK Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
14.7.2.4.1.Frozen tissues
14.7.2.4.2.FFPE tissues
14.7.2.5.The UK Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.2.5.1.Academic and Research Institutes
14.7.2.5.2.Pharmaceutical and Biotechnology Companies
14.7.2.5.3.Contract Research Organizations (CROs)
14.7.2.5.4.Others
14.7.3.Spain
14.7.3.1.Spain Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
14.7.3.1.1.Spatial Transcriptomics
14.7.3.1.1.1.Immunohistochemistry (IHC)
14.7.3.1.1.2.Fluorescence In-Situ Hybridization (FISH)
14.7.3.1.1.3.Sequencing
14.7.3.1.1.3.1.In Situ Sequencing (ISS)
14.7.3.1.1.3.2.Microdissection Sequencing
14.7.3.1.1.3.3.Others
14.7.3.1.1.4.In-Situ capturing
14.7.3.1.1.5.Microscopy based RNA imaging techniques
14.7.3.1.1.5.1.Padlock Probes and Rolling Circle Amplification
14.7.3.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
14.7.3.1.1.5.3.Branched DNA probes
14.7.3.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
14.7.3.1.2.Spatial Genomics
14.7.3.1.2.1.Fluorescence in situ Sequencing
14.7.3.1.2.2.Fluorescence Microscopy-based
14.7.3.1.2.3.Others
14.7.3.1.3.Spatial proteomics
14.7.3.1.4.Spatial metabolomics
14.7.3.1.5.Spatial multi-omics
14.7.3.1.6.Others
14.7.3.2.Spain Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
14.7.3.2.1.Products
14.7.3.2.2.Solutions
14.7.3.2.3.Consumables
14.7.3.3.Spain Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
14.7.3.3.1.Biomarker Discovery
14.7.3.3.2.Drug Development
14.7.3.3.3.Cancer Research
14.7.3.3.4.Infectious Diseases
14.7.3.3.5.Immunology
14.7.3.3.6.Metabolic Studies
14.7.3.3.7.Others
14.7.3.4.Spain Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
14.7.3.4.1.Frozen tissues
14.7.3.4.2.FFPE tissues
14.7.3.5.Spain Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.3.5.1.Academic and Research Institutes
14.7.3.5.2.Pharmaceutical and Biotechnology Companies
14.7.3.5.3.Contract Research Organizations (CROs)
14.7.3.5.4.Others
14.7.4.Germany
14.7.4.1.Germany Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
14.7.4.1.1.Spatial Transcriptomics
14.7.4.1.1.1.Immunohistochemistry (IHC)
14.7.4.1.1.2.Fluorescence In-Situ Hybridization (FISH)
14.7.4.1.1.3.Sequencing
14.7.4.1.1.3.1.In Situ Sequencing (ISS)
14.7.4.1.1.3.2.Microdissection Sequencing
14.7.4.1.1.3.3.Others
14.7.4.1.1.4.In-Situ capturing
14.7.4.1.1.5.Microscopy based RNA imaging techniques
14.7.4.1.1.5.1.Padlock Probes and Rolling Circle Amplification
14.7.4.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
14.7.4.1.1.5.3.Branched DNA probes
14.7.4.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
14.7.4.1.2.Spatial Genomics
14.7.4.1.2.1.Fluorescence in situ Sequencing
14.7.4.1.2.2.Fluorescence Microscopy-based
14.7.4.1.2.3.Others
14.7.4.1.3.Spatial proteomics
14.7.4.1.4.Spatial metabolomics
14.7.4.1.5.Spatial multi-omics
14.7.4.1.6.Others
14.7.4.2.Germany Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
14.7.4.2.1.Products
14.7.4.2.2.Solutions
14.7.4.2.3.Consumables
14.7.4.3.Germany Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
14.7.4.3.1.Biomarker Discovery
14.7.4.3.2.Drug Development
14.7.4.3.3.Cancer Research
14.7.4.3.4.Infectious Diseases
14.7.4.3.5.Immunology
14.7.4.3.6.Metabolic Studies
14.7.4.3.7.Others
14.7.4.4.Germany Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
14.7.4.4.1.Frozen tissues
14.7.4.4.2.FFPE tissues
14.7.4.5.Germany Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.4.5.1.Academic and Research Institutes
14.7.4.5.2.Pharmaceutical and Biotechnology Companies
14.7.4.5.3.Contract Research Organizations (CROs)
14.7.4.5.4.Others
14.7.5.Italy
14.7.5.1.Italy Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
14.7.5.1.1.Spatial Transcriptomics
14.7.5.1.1.1.Immunohistochemistry (IHC)
14.7.5.1.1.2.Fluorescence In-Situ Hybridization (FISH)
14.7.5.1.1.3.Sequencing
14.7.5.1.1.3.1.In Situ Sequencing (ISS)
14.7.5.1.1.3.2.Microdissection Sequencing
14.7.5.1.1.3.3.Others
14.7.5.1.1.4.In-Situ capturing
14.7.5.1.1.5.Microscopy based RNA imaging techniques
14.7.5.1.1.5.1.Padlock Probes and Rolling Circle Amplification
14.7.5.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
14.7.5.1.1.5.3.Branched DNA probes
14.7.5.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
14.7.5.1.2.Spatial Genomics
14.7.5.1.2.1.Fluorescence in situ Sequencing
14.7.5.1.2.2.Fluorescence Microscopy-based
14.7.5.1.2.3.Others
14.7.5.1.3.Spatial proteomics
14.7.5.1.4.Spatial metabolomics
14.7.5.1.5.Spatial multi-omics
14.7.5.1.6.Others
14.7.5.2.Italy Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
14.7.5.2.1.Products
14.7.5.2.2.Solutions
14.7.5.2.3.Consumables
14.7.5.3.Italy Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
14.7.5.3.1.Biomarker Discovery
14.7.5.3.2.Drug Development
14.7.5.3.3.Cancer Research
14.7.5.3.4.Infectious Diseases
14.7.5.3.5.Immunology
14.7.5.3.6.Metabolic Studies
14.7.5.3.7.Others
14.7.5.4.Italy Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
14.7.5.4.1.Frozen tissues
14.7.5.4.2.FFPE tissues
14.7.5.5.Italy Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.5.5.1.Academic and Research Institutes
14.7.5.5.2.Pharmaceutical and Biotechnology Companies
14.7.5.5.3.Contract Research Organizations (CROs)
14.7.5.5.4.Others
14.7.6.Nordic Countries
14.7.6.1.Nordic Countries Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
14.7.6.1.1.Spatial Transcriptomics
14.7.6.1.1.1.Immunohistochemistry (IHC)
14.7.6.1.1.2.Fluorescence In-Situ Hybridization (FISH)
14.7.6.1.1.3.Sequencing
14.7.6.1.1.3.1.In Situ Sequencing (ISS)
14.7.6.1.1.3.2.Microdissection Sequencing
14.7.6.1.1.3.3.Others
14.7.6.1.1.4.In-Situ capturing
14.7.6.1.1.5.Microscopy based RNA imaging techniques
14.7.6.1.1.5.1.Padlock Probes and Rolling Circle Amplification
14.7.6.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
14.7.6.1.1.5.3.Branched DNA probes
14.7.6.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
14.7.6.1.2.Spatial Genomics
14.7.6.1.2.1.Fluorescence in situ Sequencing
14.7.6.1.2.2.Fluorescence Microscopy-based
14.7.6.1.2.3.Others
14.7.6.1.3.Spatial proteomics
14.7.6.1.4.Spatial metabolomics
14.7.6.1.5.Spatial multi-omics
14.7.6.1.6.Others
14.7.6.2.Nordic Countries Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
14.7.6.2.1.Products
14.7.6.2.2.Solutions
14.7.6.2.3.Consumables
14.7.6.3.Nordic Countries Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
14.7.6.3.1.Biomarker Discovery
14.7.6.3.2.Drug Development
14.7.6.3.3.Cancer Research
14.7.6.3.4.Infectious Diseases
14.7.6.3.5.Immunology
14.7.6.3.6.Metabolic Studies
14.7.6.3.7.Others
14.7.6.4.Nordic Countries Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
14.7.6.4.1.Frozen tissues
14.7.6.4.2.FFPE tissues
14.7.6.5.Nordic Countries Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.6.5.1.Academic and Research Institutes
14.7.6.5.2.Pharmaceutical and Biotechnology Companies
14.7.6.5.3.Contract Research Organizations (CROs)
14.7.6.5.4.Others
14.7.6.6.Nordic Countries Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Country
14.7.6.6.1.Denmark
14.7.6.6.2.Finland
14.7.6.6.3.Iceland
14.7.6.6.4.Sweden
14.7.6.6.5.Norway
14.7.7.Benelux Union
14.7.7.1.Benelux Union Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
14.7.7.1.1.Spatial Transcriptomics
14.7.7.1.1.1.Immunohistochemistry (IHC)
14.7.7.1.1.2.Fluorescence In-Situ Hybridization (FISH)
14.7.7.1.1.3.Sequencing
14.7.7.1.1.3.1.In Situ Sequencing (ISS)
14.7.7.1.1.3.2.Microdissection Sequencing
14.7.7.1.1.3.3.Others
14.7.7.1.1.4.In-Situ capturing
14.7.7.1.1.5.Microscopy based RNA imaging techniques
14.7.7.1.1.5.1.Padlock Probes and Rolling Circle Amplification
14.7.7.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
14.7.7.1.1.5.3.Branched DNA probes
14.7.7.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
14.7.7.1.2.Spatial Genomics
14.7.7.1.2.1.Fluorescence in situ Sequencing
14.7.7.1.2.2.Fluorescence Microscopy-based
14.7.7.1.2.3.Others
14.7.7.1.3.Spatial proteomics
14.7.7.1.4.Spatial metabolomics
14.7.7.1.5.Spatial multi-omics
14.7.7.1.6.Others
14.7.7.2.Benelux Union Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
14.7.7.2.1.Products
14.7.7.2.2.Solutions
14.7.7.2.3.Consumables
14.7.7.3.Benelux Union Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
14.7.7.3.1.Biomarker Discovery
14.7.7.3.2.Drug Development
14.7.7.3.3.Cancer Research
14.7.7.3.4.Infectious Diseases
14.7.7.3.5.Immunology
14.7.7.3.6.Metabolic Studies
14.7.7.3.7.Others
14.7.7.4.Benelux Union Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
14.7.7.4.1.Frozen tissues
14.7.7.4.2.FFPE tissues
14.7.7.5.Benelux Union Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.7.5.1.Academic and Research Institutes
14.7.7.5.2.Pharmaceutical and Biotechnology Companies
14.7.7.5.3.Contract Research Organizations (CROs)
14.7.7.5.4.Others
14.7.7.6.Benelux Union Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Country
14.7.7.6.1.Belgium
14.7.7.6.2.The Netherlands
14.7.7.6.3.Luxembourg
14.7.8.Rest of Europe
14.7.8.1.Rest of Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
14.7.8.1.1.Spatial Transcriptomics
14.7.8.1.1.1.Immunohistochemistry (IHC)
14.7.8.1.1.2.Fluorescence In-Situ Hybridization (FISH)
14.7.8.1.1.3.Sequencing
14.7.8.1.1.3.1.In Situ Sequencing (ISS)
14.7.8.1.1.3.2.Microdissection Sequencing
14.7.8.1.1.3.3.Others
14.7.8.1.1.4.In-Situ capturing
14.7.8.1.1.5.Microscopy based RNA imaging techniques
14.7.8.1.1.5.1.Padlock Probes and Rolling Circle Amplification
14.7.8.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
14.7.8.1.1.5.3.Branched DNA probes
14.7.8.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
14.7.8.1.2.Spatial Genomics
14.7.8.1.2.1.Fluorescence in situ Sequencing
14.7.8.1.2.2.Fluorescence Microscopy-based
14.7.8.1.2.3.Others
14.7.8.1.3.Spatial proteomics
14.7.8.1.4.Spatial metabolomics
14.7.8.1.5.Spatial multi-omics
14.7.8.1.6.Others
14.7.8.2.Rest of Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
14.7.8.2.1.Products
14.7.8.2.2.Solutions
14.7.8.2.3.Consumables
14.7.8.3.Rest of Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
14.7.8.3.1.Biomarker Discovery
14.7.8.3.2.Drug Development
14.7.8.3.3.Cancer Research
14.7.8.3.4.Infectious Diseases
14.7.8.3.5.Immunology
14.7.8.3.6.Metabolic Studies
14.7.8.3.7.Others
14.7.8.4.Rest of Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
14.7.8.4.1.Frozen tissues
14.7.8.4.2.FFPE tissues
14.7.8.5.Rest of Europe Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.8.5.1.Academic and Research Institutes
14.7.8.5.2.Pharmaceutical and Biotechnology Companies
14.7.8.5.3.Contract Research Organizations (CROs)
14.7.8.5.4.Others
14.8.Key Segment for Channeling Investments
14.8.1.By Country
14.8.2.By Techniques
14.8.3.By Offerings
14.8.4.By Application
14.8.5.By Sample Type
14.8.6.By End Users
15.Asia Pacific Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
15.1.Overview
15.1.1.Asia Pacific Spatial OMICS Market Revenue (US$ Mn)
15.2.Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
15.2.1.Spatial Transcriptomics
15.2.1.1.Immunohistochemistry (IHC)
15.2.1.2.Fluorescence In-Situ Hybridization (FISH)
15.2.1.3.Sequencing
15.2.1.3.1.In Situ Sequencing (ISS)
15.2.1.3.2.Microdissection Sequencing
15.2.1.3.3.Others
15.2.1.4.In-Situ capturing
15.2.1.5.Microscopy based RNA imaging techniques
15.2.1.5.1.Padlock Probes and Rolling Circle Amplification
15.2.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
15.2.1.5.3.Branched DNA probes
15.2.1.6.Transcriptome In-Vivo Analysis (TIVA)
15.2.2.Spatial Genomics
15.2.2.1.Fluorescence in situ Sequencing
15.2.2.2.Fluorescence Microscopy-based
15.2.2.3.Others
15.2.3.Spatial proteomics
15.2.4.Spatial metabolomics
15.2.5.Spatial multi-omics
15.2.6.Others
15.3.Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
15.3.1.Products
15.3.2.Solutions
15.3.3.Consumables
15.4.Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
15.4.1.Biomarker Discovery
15.4.2.Drug Development
15.4.3.Cancer Research
15.4.4.Infectious Diseases
15.4.5.Immunology
15.4.6.Metabolic Studies
15.4.7.Others
15.5.Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.5.1.Frozen tissues
15.5.2.FFPE tissues
15.6.Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.1.Academic and Research Institutes
15.6.2.Pharmaceutical and Biotechnology Companies
15.6.3.Contract Research Organizations (CROs)
15.6.4.Others
15.7.Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1.China
15.7.1.1.China Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
15.7.1.1.1.Spatial Transcriptomics
15.7.1.1.1.1.Immunohistochemistry (IHC)
15.7.1.1.1.2.Fluorescence In-Situ Hybridization (FISH)
15.7.1.1.1.3.Sequencing
15.7.1.1.1.3.1.In Situ Sequencing (ISS)
15.7.1.1.1.3.2.Microdissection Sequencing
15.7.1.1.1.3.3.Others
15.7.1.1.1.4.In-Situ capturing
15.7.1.1.1.5.Microscopy based RNA imaging techniques
15.7.1.1.1.5.1.Padlock Probes and Rolling Circle Amplification
15.7.1.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
15.7.1.1.1.5.3.Branched DNA probes
15.7.1.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
15.7.1.1.2.Spatial Genomics
15.7.1.1.2.1.Fluorescence in situ Sequencing
15.7.1.1.2.2.Fluorescence Microscopy-based
15.7.1.1.2.3.Others
15.7.1.1.3.Spatial proteomics
15.7.1.1.4.Spatial metabolomics
15.7.1.1.5.Spatial multi-omics
15.7.1.1.6.Others
15.7.1.2.China Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
15.7.1.2.1.Products
15.7.1.2.2.Solutions
15.7.1.2.3.Consumables
15.7.1.3.China Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
15.7.1.3.1.Biomarker Discovery
15.7.1.3.2.Drug Development
15.7.1.3.3.Cancer Research
15.7.1.3.4.Infectious Diseases
15.7.1.3.5.Immunology
15.7.1.3.6.Metabolic Studies
15.7.1.3.7.Others
15.7.1.4.China Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.7.1.4.1.Frozen tissues
15.7.1.4.2.FFPE tissues
15.7.1.5.China Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.1.5.1.Academic and Research Institutes
15.7.1.5.2.Pharmaceutical and Biotechnology Companies
15.7.1.5.3.Contract Research Organizations (CROs)
15.7.1.5.4.Others
15.7.2.Japan
15.7.2.1.Japan Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
15.7.2.1.1.Spatial Transcriptomics
15.7.2.1.1.1.Immunohistochemistry (IHC)
15.7.2.1.1.2.Fluorescence In-Situ Hybridization (FISH)
15.7.2.1.1.3.Sequencing
15.7.2.1.1.3.1.In Situ Sequencing (ISS)
15.7.2.1.1.3.2.Microdissection Sequencing
15.7.2.1.1.3.3.Others
15.7.2.1.1.4.In-Situ capturing
15.7.2.1.1.5.Microscopy based RNA imaging techniques
15.7.2.1.1.5.1.Padlock Probes and Rolling Circle Amplification
15.7.2.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
15.7.2.1.1.5.3.Branched DNA probes
15.7.2.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
15.7.2.1.2.Spatial Genomics
15.7.2.1.2.1.Fluorescence in situ Sequencing
15.7.2.1.2.2.Fluorescence Microscopy-based
15.7.2.1.2.3.Others
15.7.2.1.3.Spatial proteomics
15.7.2.1.4.Spatial metabolomics
15.7.2.1.5.Spatial multi-omics
15.7.2.1.6.Others
15.7.2.2.Japan Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
15.7.2.2.1.Products
15.7.2.2.2.Solutions
15.7.2.2.3.Consumables
15.7.2.3.Japan Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
15.7.2.3.1.Biomarker Discovery
15.7.2.3.2.Drug Development
15.7.2.3.3.Cancer Research
15.7.2.3.4.Infectious Diseases
15.7.2.3.5.Immunology
15.7.2.3.6.Metabolic Studies
15.7.2.3.7.Others
15.7.2.4.Japan Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.7.2.4.1.Frozen tissues
15.7.2.4.2.FFPE tissues
15.7.2.5.Japan Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.2.5.1.Academic and Research Institutes
15.7.2.5.2.Pharmaceutical and Biotechnology Companies
15.7.2.5.3.Contract Research Organizations (CROs)
15.7.2.5.4.Others
15.7.3.India
15.7.3.1.India Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
15.7.3.1.1.Spatial Transcriptomics
15.7.3.1.1.1.Immunohistochemistry (IHC)
15.7.3.1.1.2.Fluorescence In-Situ Hybridization (FISH)
15.7.3.1.1.3.Sequencing
15.7.3.1.1.3.1.In Situ Sequencing (ISS)
15.7.3.1.1.3.2.Microdissection Sequencing
15.7.3.1.1.3.3.Others
15.7.3.1.1.4.In-Situ capturing
15.7.3.1.1.5.Microscopy based RNA imaging techniques
15.7.3.1.1.5.1.Padlock Probes and Rolling Circle Amplification
15.7.3.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
15.7.3.1.1.5.3.Branched DNA probes
15.7.3.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
15.7.3.1.2.Spatial Genomics
15.7.3.1.2.1.Fluorescence in situ Sequencing
15.7.3.1.2.2.Fluorescence Microscopy-based
15.7.3.1.2.3.Others
15.7.3.1.3.Spatial proteomics
15.7.3.1.4.Spatial metabolomics
15.7.3.1.5.Spatial multi-omics
15.7.3.1.6.Others
15.7.3.2.India Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
15.7.3.2.1.Products
15.7.3.2.2.Solutions
15.7.3.2.3.Consumables
15.7.3.3.India Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
15.7.3.3.1.Biomarker Discovery
15.7.3.3.2.Drug Development
15.7.3.3.3.Cancer Research
15.7.3.3.4.Infectious Diseases
15.7.3.3.5.Immunology
15.7.3.3.6.Metabolic Studies
15.7.3.3.7.Others
15.7.3.4.India Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.7.3.4.1.Frozen tissues
15.7.3.4.2.FFPE tissues
15.7.3.5.India Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.3.5.1.Academic and Research Institutes
15.7.3.5.2.Pharmaceutical and Biotechnology Companies
15.7.3.5.3.Contract Research Organizations (CROs)
15.7.3.5.4.Others
15.7.4.New Zealand
15.7.4.1.New Zealand Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
15.7.4.1.1.Spatial Transcriptomics
15.7.4.1.1.1.Immunohistochemistry (IHC)
15.7.4.1.1.2.Fluorescence In-Situ Hybridization (FISH)
15.7.4.1.1.3.Sequencing
15.7.4.1.1.3.1.In Situ Sequencing (ISS)
15.7.4.1.1.3.2.Microdissection Sequencing
15.7.4.1.1.3.3.Others
15.7.4.1.1.4.In-Situ capturing
15.7.4.1.1.5.Microscopy based RNA imaging techniques
15.7.4.1.1.5.1.Padlock Probes and Rolling Circle Amplification
15.7.4.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
15.7.4.1.1.5.3.Branched DNA probes
15.7.4.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
15.7.4.1.2.Spatial Genomics
15.7.4.1.2.1.Fluorescence in situ Sequencing
15.7.4.1.2.2.Fluorescence Microscopy-based
15.7.4.1.2.3.Others
15.7.4.1.3.Spatial proteomics
15.7.4.1.4.Spatial metabolomics
15.7.4.1.5.Spatial multi-omics
15.7.4.1.6.Others
15.7.4.2.New Zealand Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
15.7.4.2.1.Products
15.7.4.2.2.Solutions
15.7.4.2.3.Consumables
15.7.4.3.New Zealand Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
15.7.4.3.1.Biomarker Discovery
15.7.4.3.2.Drug Development
15.7.4.3.3.Cancer Research
15.7.4.3.4.Infectious Diseases
15.7.4.3.5.Immunology
15.7.4.3.6.Metabolic Studies
15.7.4.3.7.Others
15.7.4.4.New Zealand Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.7.4.4.1.Frozen tissues
15.7.4.4.2.FFPE tissues
15.7.4.5.New Zealand Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.4.5.1.Academic and Research Institutes
15.7.4.5.2.Pharmaceutical and Biotechnology Companies
15.7.4.5.3.Contract Research Organizations (CROs)
15.7.4.5.4.Others
15.7.5.Australia
15.7.5.1.Australia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
15.7.5.1.1.Spatial Transcriptomics
15.7.5.1.1.1.Immunohistochemistry (IHC)
15.7.5.1.1.2.Fluorescence In-Situ Hybridization (FISH)
15.7.5.1.1.3.Sequencing
15.7.5.1.1.3.1.In Situ Sequencing (ISS)
15.7.5.1.1.3.2.Microdissection Sequencing
15.7.5.1.1.3.3.Others
15.7.5.1.1.4.In-Situ capturing
15.7.5.1.1.5.Microscopy based RNA imaging techniques
15.7.5.1.1.5.1.Padlock Probes and Rolling Circle Amplification
15.7.5.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
15.7.5.1.1.5.3.Branched DNA probes
15.7.5.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
15.7.5.1.2.Spatial Genomics
15.7.5.1.2.1.Fluorescence in situ Sequencing
15.7.5.1.2.2.Fluorescence Microscopy-based
15.7.5.1.2.3.Others
15.7.5.1.3.Spatial proteomics
15.7.5.1.4.Spatial metabolomics
15.7.5.1.5.Spatial multi-omics
15.7.5.1.6.Others
15.7.5.2.Australia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
15.7.5.2.1.Products
15.7.5.2.2.Solutions
15.7.5.2.3.Consumables
15.7.5.3.Australia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
15.7.5.3.1.Biomarker Discovery
15.7.5.3.2.Drug Development
15.7.5.3.3.Cancer Research
15.7.5.3.4.Infectious Diseases
15.7.5.3.5.Immunology
15.7.5.3.6.Metabolic Studies
15.7.5.3.7.Others
15.7.5.4.Australia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.7.5.4.1.Frozen tissues
15.7.5.4.2.FFPE tissues
15.7.5.5.Australia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.5.5.1.Academic and Research Institutes
15.7.5.5.2.Pharmaceutical and Biotechnology Companies
15.7.5.5.3.Contract Research Organizations (CROs)
15.7.5.5.4.Others
15.7.6.South Korea
15.7.6.1.South Korea Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
15.7.6.1.1.Spatial Transcriptomics
15.7.6.1.1.1.Immunohistochemistry (IHC)
15.7.6.1.1.2.Fluorescence In-Situ Hybridization (FISH)
15.7.6.1.1.3.Sequencing
15.7.6.1.1.3.1.In Situ Sequencing (ISS)
15.7.6.1.1.3.2.Microdissection Sequencing
15.7.6.1.1.3.3.Others
15.7.6.1.1.4.In-Situ capturing
15.7.6.1.1.5.Microscopy based RNA imaging techniques
15.7.6.1.1.5.1.Padlock Probes and Rolling Circle Amplification
15.7.6.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
15.7.6.1.1.5.3.Branched DNA probes
15.7.6.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
15.7.6.1.2.Spatial Genomics
15.7.6.1.2.1.Fluorescence in situ Sequencing
15.7.6.1.2.2.Fluorescence Microscopy-based
15.7.6.1.2.3.Others
15.7.6.1.3.Spatial proteomics
15.7.6.1.4.Spatial metabolomics
15.7.6.1.5.Spatial multi-omics
15.7.6.1.6.Others
15.7.6.2.South Korea Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
15.7.6.2.1.Products
15.7.6.2.2.Solutions
15.7.6.2.3.Consumables
15.7.6.3.South Korea Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
15.7.6.3.1.Biomarker Discovery
15.7.6.3.2.Drug Development
15.7.6.3.3.Cancer Research
15.7.6.3.4.Infectious Diseases
15.7.6.3.5.Immunology
15.7.6.3.6.Metabolic Studies
15.7.6.3.7.Others
15.7.6.4.South Korea Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.7.6.4.1.Frozen tissues
15.7.6.4.2.FFPE tissues
15.7.6.5.South Korea Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.6.5.1.Academic and Research Institutes
15.7.6.5.2.Pharmaceutical and Biotechnology Companies
15.7.6.5.3.Contract Research Organizations (CROs)
15.7.6.5.4.Others
15.7.7.Southeast Asia
15.7.7.1.Southeast Asia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
15.7.7.1.1.Spatial Transcriptomics
15.7.7.1.1.1.Immunohistochemistry (IHC)
15.7.7.1.1.2.Fluorescence In-Situ Hybridization (FISH)
15.7.7.1.1.3.Sequencing
15.7.7.1.1.3.1.In Situ Sequencing (ISS)
15.7.7.1.1.3.2.Microdissection Sequencing
15.7.7.1.1.3.3.Others
15.7.7.1.1.4.In-Situ capturing
15.7.7.1.1.5.Microscopy based RNA imaging techniques
15.7.7.1.1.5.1.Padlock Probes and Rolling Circle Amplification
15.7.7.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
15.7.7.1.1.5.3.Branched DNA probes
15.7.7.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
15.7.7.1.2.Spatial Genomics
15.7.7.1.2.1.Fluorescence in situ Sequencing
15.7.7.1.2.2.Fluorescence Microscopy-based
15.7.7.1.2.3.Others
15.7.7.1.3.Spatial proteomics
15.7.7.1.4.Spatial metabolomics
15.7.7.1.5.Spatial multi-omics
15.7.7.1.6.Others
15.7.7.2.Southeast Asia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
15.7.7.2.1.Products
15.7.7.2.2.Solutions
15.7.7.2.3.Consumables
15.7.7.3.Southeast Asia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
15.7.7.3.1.Biomarker Discovery
15.7.7.3.2.Drug Development
15.7.7.3.3.Cancer Research
15.7.7.3.4.Infectious Diseases
15.7.7.3.5.Immunology
15.7.7.3.6.Metabolic Studies
15.7.7.3.7.Others
15.7.7.4.Southeast Asia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.7.7.4.1.Frozen tissues
15.7.7.4.2.FFPE tissues
15.7.7.5.Southeast Asia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.7.5.1.Academic and Research Institutes
15.7.7.5.2.Pharmaceutical and Biotechnology Companies
15.7.7.5.3.Contract Research Organizations (CROs)
15.7.7.5.4.Others
15.7.7.6.Southeast Asia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Country
15.7.7.6.1.Indonesia
15.7.7.6.2.Thailand
15.7.7.6.3.Malaysia
15.7.7.6.4.Singapore
15.7.7.6.5.Rest of Southeast Asia
15.7.8.Rest of Asia Pacific
15.7.8.1.Rest of Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
15.7.8.1.1.Spatial Transcriptomics
15.7.8.1.1.1.Immunohistochemistry (IHC)
15.7.8.1.1.2.Fluorescence In-Situ Hybridization (FISH)
15.7.8.1.1.3.Sequencing
15.7.8.1.1.3.1.In Situ Sequencing (ISS)
15.7.8.1.1.3.2.Microdissection Sequencing
15.7.8.1.1.3.3.Others
15.7.8.1.1.4.In-Situ capturing
15.7.8.1.1.5.Microscopy based RNA imaging techniques
15.7.8.1.1.5.1.Padlock Probes and Rolling Circle Amplification
15.7.8.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
15.7.8.1.1.5.3.Branched DNA probes
15.7.8.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
15.7.8.1.2.Spatial Genomics
15.7.8.1.2.1.Fluorescence in situ Sequencing
15.7.8.1.2.2.Fluorescence Microscopy-based
15.7.8.1.2.3.Others
15.7.8.1.3.Spatial proteomics
15.7.8.1.4.Spatial metabolomics
15.7.8.1.5.Spatial multi-omics
15.7.8.1.6.Others
15.7.8.2.Rest of Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
15.7.8.2.1.Products
15.7.8.2.2.Solutions
15.7.8.2.3.Consumables
15.7.8.3.Rest of Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
15.7.8.3.1.Biomarker Discovery
15.7.8.3.2.Drug Development
15.7.8.3.3.Cancer Research
15.7.8.3.4.Infectious Diseases
15.7.8.3.5.Immunology
15.7.8.3.6.Metabolic Studies
15.7.8.3.7.Others
15.7.8.4.Rest of Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
15.7.8.4.1.Frozen tissues
15.7.8.4.2.FFPE tissues
15.7.8.5.Rest of Asia Pacific Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.8.5.1.Academic and Research Institutes
15.7.8.5.2.Pharmaceutical and Biotechnology Companies
15.7.8.5.3.Contract Research Organizations (CROs)
15.7.8.5.4.Others
15.8.Key Segment for Channeling Investments
15.8.1.By Country
15.8.2.By Techniques
15.8.3.By Offerings
15.8.4.By Application
15.8.5.By Sample Type
15.8.6.By End Users
16.Middle East and Africa Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
16.1.Overview
16.1.1.Middle East and Africa Spatial OMICS Market Revenue (US$ Mn)
16.2.Middle East and Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
16.2.1.Spatial Transcriptomics
16.2.1.1.Immunohistochemistry (IHC)
16.2.1.2.Fluorescence In-Situ Hybridization (FISH)
16.2.1.3.Sequencing
16.2.1.3.1.In Situ Sequencing (ISS)
16.2.1.3.2.Microdissection Sequencing
16.2.1.3.3.Others
16.2.1.4.In-Situ capturing
16.2.1.5.Microscopy based RNA imaging techniques
16.2.1.5.1.Padlock Probes and Rolling Circle Amplification
16.2.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
16.2.1.5.3.Branched DNA probes
16.2.1.6.Transcriptome In-Vivo Analysis (TIVA)
16.2.2.Spatial Genomics
16.2.2.1.Fluorescence in situ Sequencing
16.2.2.2.Fluorescence Microscopy-based
16.2.2.3.Others
16.2.3.Spatial proteomics
16.2.4.Spatial metabolomics
16.2.5.Spatial multi-omics
16.2.6.Others
16.3.Middle East and Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
16.3.1.Products
16.3.2.Solutions
16.3.3.Consumables
16.4.Middle East and Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
16.4.1.Biomarker Discovery
16.4.2.Drug Development
16.4.3.Cancer Research
16.4.4.Infectious Diseases
16.4.5.Immunology
16.4.6.Metabolic Studies
16.4.7.Others
16.5.Middle East and Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.5.1.Frozen tissues
16.5.2.FFPE tissues
16.6.Middle East and Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.Academic and Research Institutes
16.6.2.Pharmaceutical and Biotechnology Companies
16.6.3.Contract Research Organizations (CROs)
16.6.4.Others
16.7.Middle East and Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Country
16.7.1.Saudi Arabia
16.7.1.1.Saudi Arabia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
16.7.1.1.1.Spatial Transcriptomics
16.7.1.1.1.1.Immunohistochemistry (IHC)
16.7.1.1.1.2.Fluorescence In-Situ Hybridization (FISH)
16.7.1.1.1.3.Sequencing
16.7.1.1.1.3.1.In Situ Sequencing (ISS)
16.7.1.1.1.3.2.Microdissection Sequencing
16.7.1.1.1.3.3.Others
16.7.1.1.1.4.In-Situ capturing
16.7.1.1.1.5.Microscopy based RNA imaging techniques
16.7.1.1.1.5.1.Padlock Probes and Rolling Circle Amplification
16.7.1.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
16.7.1.1.1.5.3.Branched DNA probes
16.7.1.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
16.7.1.1.2.Spatial Genomics
16.7.1.1.2.1.Fluorescence in situ Sequencing
16.7.1.1.2.2.Fluorescence Microscopy-based
16.7.1.1.2.3.Others
16.7.1.1.3.Spatial proteomics
16.7.1.1.4.Spatial metabolomics
16.7.1.1.5.Spatial multi-omics
16.7.1.1.6.Others
16.7.1.2.Saudi Arabia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
16.7.1.2.1.Products
16.7.1.2.2.Solutions
16.7.1.2.3.Consumables
16.7.1.3.Saudi Arabia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
16.7.1.3.1.Biomarker Discovery
16.7.1.3.2.Drug Development
16.7.1.3.3.Cancer Research
16.7.1.3.4.Infectious Diseases
16.7.1.3.5.Immunology
16.7.1.3.6.Metabolic Studies
16.7.1.3.7.Others
16.7.1.4.Saudi Arabia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.7.1.4.1.Frozen tissues
16.7.1.4.2.FFPE tissues
16.7.1.5.Saudi Arabia Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.1.5.1.Academic and Research Institutes
16.7.1.5.2.Pharmaceutical and Biotechnology Companies
16.7.1.5.3.Contract Research Organizations (CROs)
16.7.1.5.4.Others
16.7.2.UAE
16.7.2.1.UAE Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
16.7.2.1.1.Spatial Transcriptomics
16.7.2.1.1.1.Immunohistochemistry (IHC)
16.7.2.1.1.2.Fluorescence In-Situ Hybridization (FISH)
16.7.2.1.1.3.Sequencing
16.7.2.1.1.3.1.In Situ Sequencing (ISS)
16.7.2.1.1.3.2.Microdissection Sequencing
16.7.2.1.1.3.3.Others
16.7.2.1.1.4.In-Situ capturing
16.7.2.1.1.5.Microscopy based RNA imaging techniques
16.7.2.1.1.5.1.Padlock Probes and Rolling Circle Amplification
16.7.2.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
16.7.2.1.1.5.3.Branched DNA probes
16.7.2.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
16.7.2.1.2.Spatial Genomics
16.7.2.1.2.1.Fluorescence in situ Sequencing
16.7.2.1.2.2.Fluorescence Microscopy-based
16.7.2.1.2.3.Others
16.7.2.1.3.Spatial proteomics
16.7.2.1.4.Spatial metabolomics
16.7.2.1.5.Spatial multi-omics
16.7.2.1.6.Others
16.7.2.2.UAE Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
16.7.2.2.1.Products
16.7.2.2.2.Solutions
16.7.2.2.3.Consumables
16.7.2.3.UAE Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
16.7.2.3.1.Biomarker Discovery
16.7.2.3.2.Drug Development
16.7.2.3.3.Cancer Research
16.7.2.3.4.Infectious Diseases
16.7.2.3.5.Immunology
16.7.2.3.6.Metabolic Studies
16.7.2.3.7.Others
16.7.2.4.UAE Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.7.2.4.1.Frozen tissues
16.7.2.4.2.FFPE tissues
16.7.2.5.UAE Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.2.5.1.Academic and Research Institutes
16.7.2.5.2.Pharmaceutical and Biotechnology Companies
16.7.2.5.3.Contract Research Organizations (CROs)
16.7.2.5.4.Others
16.7.3.Egypt
16.7.3.1.Egypt Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
16.7.3.1.1.Spatial Transcriptomics
16.7.3.1.1.1.Immunohistochemistry (IHC)
16.7.3.1.1.2.Fluorescence In-Situ Hybridization (FISH)
16.7.3.1.1.3.Sequencing
16.7.3.1.1.3.1.In Situ Sequencing (ISS)
16.7.3.1.1.3.2.Microdissection Sequencing
16.7.3.1.1.3.3.Others
16.7.3.1.1.4.In-Situ capturing
16.7.3.1.1.5.Microscopy based RNA imaging techniques
16.7.3.1.1.5.1.Padlock Probes and Rolling Circle Amplification
16.7.3.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
16.7.3.1.1.5.3.Branched DNA probes
16.7.3.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
16.7.3.1.2.Spatial Genomics
16.7.3.1.2.1.Fluorescence in situ Sequencing
16.7.3.1.2.2.Fluorescence Microscopy-based
16.7.3.1.2.3.Others
16.7.3.1.3.Spatial proteomics
16.7.3.1.4.Spatial metabolomics
16.7.3.1.5.Spatial multi-omics
16.7.3.1.6.Others
16.7.3.2.Egypt Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
16.7.3.2.1.Products
16.7.3.2.2.Solutions
16.7.3.2.3.Consumables
16.7.3.3.Egypt Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
16.7.3.3.1.Biomarker Discovery
16.7.3.3.2.Drug Development
16.7.3.3.3.Cancer Research
16.7.3.3.4.Infectious Diseases
16.7.3.3.5.Immunology
16.7.3.3.6.Metabolic Studies
16.7.3.3.7.Others
16.7.3.4.Egypt Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.7.3.4.1.Frozen tissues
16.7.3.4.2.FFPE tissues
16.7.3.5.Egypt Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.3.5.1.Academic and Research Institutes
16.7.3.5.2.Pharmaceutical and Biotechnology Companies
16.7.3.5.3.Contract Research Organizations (CROs)
16.7.3.5.4.Others
16.7.4.Kuwait
16.7.4.1.Kuwait Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
16.7.4.1.1.Spatial Transcriptomics
16.7.4.1.1.1.Immunohistochemistry (IHC)
16.7.4.1.1.2.Fluorescence In-Situ Hybridization (FISH)
16.7.4.1.1.3.Sequencing
16.7.4.1.1.3.1.In Situ Sequencing (ISS)
16.7.4.1.1.3.2.Microdissection Sequencing
16.7.4.1.1.3.3.Others
16.7.4.1.1.4.In-Situ capturing
16.7.4.1.1.5.Microscopy based RNA imaging techniques
16.7.4.1.1.5.1.Padlock Probes and Rolling Circle Amplification
16.7.4.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
16.7.4.1.1.5.3.Branched DNA probes
16.7.4.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
16.7.4.1.2.Spatial Genomics
16.7.4.1.2.1.Fluorescence in situ Sequencing
16.7.4.1.2.2.Fluorescence Microscopy-based
16.7.4.1.2.3.Others
16.7.4.1.3.Spatial proteomics
16.7.4.1.4.Spatial metabolomics
16.7.4.1.5.Spatial multi-omics
16.7.4.1.6.Others
16.7.4.2.Kuwait Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
16.7.4.2.1.Products
16.7.4.2.2.Solutions
16.7.4.2.3.Consumables
16.7.4.3.Kuwait Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
16.7.4.3.1.Biomarker Discovery
16.7.4.3.2.Drug Development
16.7.4.3.3.Cancer Research
16.7.4.3.4.Infectious Diseases
16.7.4.3.5.Immunology
16.7.4.3.6.Metabolic Studies
16.7.4.3.7.Others
16.7.4.4.Kuwait Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.7.4.4.1.Frozen tissues
16.7.4.4.2.FFPE tissues
16.7.4.5.Kuwait Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.4.5.1.Academic and Research Institutes
16.7.4.5.2.Pharmaceutical and Biotechnology Companies
16.7.4.5.3.Contract Research Organizations (CROs)
16.7.4.5.4.Others
16.7.5.South Africa
16.7.5.1.South Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
16.7.5.1.1.Spatial Transcriptomics
16.7.5.1.1.1.Immunohistochemistry (IHC)
16.7.5.1.1.2.Fluorescence In-Situ Hybridization (FISH)
16.7.5.1.1.3.Sequencing
16.7.5.1.1.3.1.In Situ Sequencing (ISS)
16.7.5.1.1.3.2.Microdissection Sequencing
16.7.5.1.1.3.3.Others
16.7.5.1.1.4.In-Situ capturing
16.7.5.1.1.5.Microscopy based RNA imaging techniques
16.7.5.1.1.5.1.Padlock Probes and Rolling Circle Amplification
16.7.5.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
16.7.5.1.1.5.3.Branched DNA probes
16.7.5.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
16.7.5.1.2.Spatial Genomics
16.7.5.1.2.1.Fluorescence in situ Sequencing
16.7.5.1.2.2.Fluorescence Microscopy-based
16.7.5.1.2.3.Others
16.7.5.1.3.Spatial proteomics
16.7.5.1.4.Spatial metabolomics
16.7.5.1.5.Spatial multi-omics
16.7.5.1.6.Others
16.7.5.2.South Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
16.7.5.2.1.Products
16.7.5.2.2.Solutions
16.7.5.2.3.Consumables
16.7.5.3.South Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
16.7.5.3.1.Biomarker Discovery
16.7.5.3.2.Drug Development
16.7.5.3.3.Cancer Research
16.7.5.3.4.Infectious Diseases
16.7.5.3.5.Immunology
16.7.5.3.6.Metabolic Studies
16.7.5.3.7.Others
16.7.5.4.South Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.7.5.4.1.Frozen tissues
16.7.5.4.2.FFPE tissues
16.7.5.5.South Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.5.5.1.Academic and Research Institutes
16.7.5.5.2.Pharmaceutical and Biotechnology Companies
16.7.5.5.3.Contract Research Organizations (CROs)
16.7.5.5.4.Others
16.7.6.Rest of Middle East & Africa
16.7.6.1.Rest of Middle East & Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
16.7.6.1.1.Spatial Transcriptomics
16.7.6.1.1.1.Immunohistochemistry (IHC)
16.7.6.1.1.2.Fluorescence In-Situ Hybridization (FISH)
16.7.6.1.1.3.Sequencing
16.7.6.1.1.3.1.In Situ Sequencing (ISS)
16.7.6.1.1.3.2.Microdissection Sequencing
16.7.6.1.1.3.3.Others
16.7.6.1.1.4.In-Situ capturing
16.7.6.1.1.5.Microscopy based RNA imaging techniques
16.7.6.1.1.5.1.Padlock Probes and Rolling Circle Amplification
16.7.6.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
16.7.6.1.1.5.3.Branched DNA probes
16.7.6.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
16.7.6.1.2.Spatial Genomics
16.7.6.1.2.1.Fluorescence in situ Sequencing
16.7.6.1.2.2.Fluorescence Microscopy-based
16.7.6.1.2.3.Others
16.7.6.1.3.Spatial proteomics
16.7.6.1.4.Spatial metabolomics
16.7.6.1.5.Spatial multi-omics
16.7.6.1.6.Others
16.7.6.2.Rest of Middle East & Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
16.7.6.2.1.Products
16.7.6.2.2.Solutions
16.7.6.2.3.Consumables
16.7.6.3.Rest of Middle East & Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
16.7.6.3.1.Biomarker Discovery
16.7.6.3.2.Drug Development
16.7.6.3.3.Cancer Research
16.7.6.3.4.Infectious Diseases
16.7.6.3.5.Immunology
16.7.6.3.6.Metabolic Studies
16.7.6.3.7.Others
16.7.6.4.Rest of Middle East & Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
16.7.6.4.1.Frozen tissues
16.7.6.4.2.FFPE tissues
16.7.6.5.Rest of Middle East & Africa Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.6.5.1.Academic and Research Institutes
16.7.6.5.2.Pharmaceutical and Biotechnology Companies
16.7.6.5.3.Contract Research Organizations (CROs)
16.7.6.5.4.Others
16.8.Key Segment for Channeling Investments
16.8.1.By Country
16.8.2.By Techniques
16.8.3.By Offerings
16.8.4.By Application
16.8.5.By Sample Type
16.8.6.By End Users
17.Latin America Spatial OMICS Market Analysis and Forecasts, 2023 – 2031
17.1.Overview
17.1.1.Latin America Spatial OMICS Market Revenue (US$ Mn)
17.2.Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
17.2.1.Spatial Transcriptomics
17.2.1.1.Immunohistochemistry (IHC)
17.2.1.2.Fluorescence In-Situ Hybridization (FISH)
17.2.1.3.Sequencing
17.2.1.3.1.In Situ Sequencing (ISS)
17.2.1.3.2.Microdissection Sequencing
17.2.1.3.3.Others
17.2.1.4.In-Situ capturing
17.2.1.5.Microscopy based RNA imaging techniques
17.2.1.5.1.Padlock Probes and Rolling Circle Amplification
17.2.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
17.2.1.5.3.Branched DNA probes
17.2.1.6.Transcriptome In-Vivo Analysis (TIVA)
17.2.2.Spatial Genomics
17.2.2.1.Fluorescence in situ Sequencing
17.2.2.2.Fluorescence Microscopy-based
17.2.2.3.Others
17.2.3.Spatial proteomics
17.2.4.Spatial metabolomics
17.2.5.Spatial multi-omics
17.2.6.Others
17.3.Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
17.3.1.Products
17.3.2.Solutions
17.3.3.Consumables
17.4.Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
17.4.1.Biomarker Discovery
17.4.2.Drug Development
17.4.3.Cancer Research
17.4.4.Infectious Diseases
17.4.5.Immunology
17.4.6.Metabolic Studies
17.4.7.Others
17.5.Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.5.1.Frozen tissues
17.5.2.FFPE tissues
17.6.Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
17.6.1.Academic and Research Institutes
17.6.2.Pharmaceutical and Biotechnology Companies
17.6.3.Contract Research Organizations (CROs)
17.6.4.Others
17.7.Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1.Brazil
17.7.1.1.Brazil Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
17.7.1.1.1.Spatial Transcriptomics
17.7.1.1.1.1.Immunohistochemistry (IHC)
17.7.1.1.1.2.Fluorescence In-Situ Hybridization (FISH)
17.7.1.1.1.3.Sequencing
17.7.1.1.1.3.1.In Situ Sequencing (ISS)
17.7.1.1.1.3.2.Microdissection Sequencing
17.7.1.1.1.3.3.Others
17.7.1.1.1.4.In-Situ capturing
17.7.1.1.1.5.Microscopy based RNA imaging techniques
17.7.1.1.1.5.1.Padlock Probes and Rolling Circle Amplification
17.7.1.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
17.7.1.1.1.5.3.Branched DNA probes
17.7.1.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
17.7.1.1.2.Spatial Genomics
17.7.1.1.2.1.Fluorescence in situ Sequencing
17.7.1.1.2.2.Fluorescence Microscopy-based
17.7.1.1.2.3.Others
17.7.1.1.3.Spatial proteomics
17.7.1.1.4.Spatial metabolomics
17.7.1.1.5.Spatial multi-omics
17.7.1.1.6.Others
17.7.1.2.Brazil Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
17.7.1.2.1.Products
17.7.1.2.2.Solutions
17.7.1.2.3.Consumables
17.7.1.3.Brazil Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
17.7.1.3.1.Biomarker Discovery
17.7.1.3.2.Drug Development
17.7.1.3.3.Cancer Research
17.7.1.3.4.Infectious Diseases
17.7.1.3.5.Immunology
17.7.1.3.6.Metabolic Studies
17.7.1.3.7.Others
17.7.1.4.Brazil Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.7.1.4.1.Frozen tissues
17.7.1.4.2.FFPE tissues
17.7.1.5.Brazil Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
17.7.1.5.1.Academic and Research Institutes
17.7.1.5.2.Pharmaceutical and Biotechnology Companies
17.7.1.5.3.Contract Research Organizations (CROs)
17.7.1.5.4.Others
17.7.2.Argentina
17.7.2.1.Argentina Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
17.7.2.1.1.Spatial Transcriptomics
17.7.2.1.1.1.Immunohistochemistry (IHC)
17.7.2.1.1.2.Fluorescence In-Situ Hybridization (FISH)
17.7.2.1.1.3.Sequencing
17.7.2.1.1.3.1.In Situ Sequencing (ISS)
17.7.2.1.1.3.2.Microdissection Sequencing
17.7.2.1.1.3.3.Others
17.7.2.1.1.4.In-Situ capturing
17.7.2.1.1.5.Microscopy based RNA imaging techniques
17.7.2.1.1.5.1.Padlock Probes and Rolling Circle Amplification
17.7.2.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
17.7.2.1.1.5.3.Branched DNA probes
17.7.2.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
17.7.2.1.2.Spatial Genomics
17.7.2.1.2.1.Fluorescence in situ Sequencing
17.7.2.1.2.2.Fluorescence Microscopy-based
17.7.2.1.2.3.Others
17.7.2.1.3.Spatial proteomics
17.7.2.1.4.Spatial metabolomics
17.7.2.1.5.Spatial multi-omics
17.7.2.1.6.Others
17.7.2.2.Argentina Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
17.7.2.2.1.Products
17.7.2.2.2.Solutions
17.7.2.2.3.Consumables
17.7.2.3.Argentina Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
17.7.2.3.1.Biomarker Discovery
17.7.2.3.2.Drug Development
17.7.2.3.3.Cancer Research
17.7.2.3.4.Infectious Diseases
17.7.2.3.5.Immunology
17.7.2.3.6.Metabolic Studies
17.7.2.3.7.Others
17.7.2.4.Argentina Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.7.2.4.1.Frozen tissues
17.7.2.4.2.FFPE tissues
17.7.2.5.Argentina Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
17.7.2.5.1.Academic and Research Institutes
17.7.2.5.2.Pharmaceutical and Biotechnology Companies
17.7.2.5.3.Contract Research Organizations (CROs)
17.7.2.5.4.Others
17.7.3.Rest of Latin America
17.7.3.1.Rest of Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Techniques
17.7.3.1.1.Spatial Transcriptomics
17.7.3.1.1.1.Immunohistochemistry (IHC)
17.7.3.1.1.2.Fluorescence In-Situ Hybridization (FISH)
17.7.3.1.1.3.Sequencing
17.7.3.1.1.3.1.In Situ Sequencing (ISS)
17.7.3.1.1.3.2.Microdissection Sequencing
17.7.3.1.1.3.3.Others
17.7.3.1.1.4.In-Situ capturing
17.7.3.1.1.5.Microscopy based RNA imaging techniques
17.7.3.1.1.5.1.Padlock Probes and Rolling Circle Amplification
17.7.3.1.1.5.2.Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)
17.7.3.1.1.5.3.Branched DNA probes
17.7.3.1.1.6.Transcriptome In-Vivo Analysis (TIVA)
17.7.3.1.2.Spatial Genomics
17.7.3.1.2.1.Fluorescence in situ Sequencing
17.7.3.1.2.2.Fluorescence Microscopy-based
17.7.3.1.2.3.Others
17.7.3.1.3.Spatial proteomics
17.7.3.1.4.Spatial metabolomics
17.7.3.1.5.Spatial multi-omics
17.7.3.1.6.Others
17.7.3.2.Rest of Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Offerings
17.7.3.2.1.Products
17.7.3.2.2.Solutions
17.7.3.2.3.Consumables
17.7.3.3.Rest of Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Application
17.7.3.3.1.Biomarker Discovery
17.7.3.3.2.Drug Development
17.7.3.3.3.Cancer Research
17.7.3.3.4.Infectious Diseases
17.7.3.3.5.Immunology
17.7.3.3.6.Metabolic Studies
17.7.3.3.7.Others
17.7.3.4.Rest of Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By Sample Type
17.7.3.4.1.Frozen tissues
17.7.3.4.2.FFPE tissues
17.7.3.5.Rest of Latin America Spatial OMICS Market Revenue (US$ Mn) and Forecasts, By End Users
17.7.3.5.1.Academic and Research Institutes
17.7.3.5.2.Pharmaceutical and Biotechnology Companies
17.7.3.5.3.Contract Research Organizations (CROs)
17.7.3.5.4.Others
17.8.Key Segment for Channeling Investments
17.8.1.By Country
17.8.2.By Techniques
17.8.3.By Offerings
17.8.4.By Application
17.8.5.By Sample Type
17.8.6.By End Users
18.Competitive Benchmarking
18.1.Market Share Analysis, 2022
18.2.Global Presence and Growth Strategies
18.2.1.Mergers and Acquisitions
18.2.2.Product Launches
18.2.3.Investments Trends
18.2.4.R&D Initiatives
19.Player Profiles
19.1.10x Genomics
19.1.1.Company Details
19.1.2.Company Overview
19.1.3.Product Offerings
19.1.4.Key Developments
19.1.5.Financial Analysis
19.1.6.SWOT Analysis
19.1.7.Business Strategies
19.2.Agilent Technologies Inc
19.2.1.Company Details
19.2.2.Company Overview
19.2.3.Product Offerings
19.2.4.Key Developments
19.2.5.Financial Analysis
19.2.6.SWOT Analysis
19.2.7.Business Strategies
19.3.Akoya Biosciences
19.3.1.Company Details
19.3.2.Company Overview
19.3.3.Product Offerings
19.3.4.Key Developments
19.3.5.Financial Analysis
19.3.6.SWOT Analysis
19.3.7.Business Strategies
19.4.Bio-Techne
19.4.1.Company Details
19.4.2.Company Overview
19.4.3.Product Offerings
19.4.4.Key Developments
19.4.5.Financial Analysis
19.4.6.SWOT Analysis
19.4.7.Business Strategies
19.5.CD Genomics.
19.5.1.Company Details
19.5.2.Company Overview
19.5.3.Product Offerings
19.5.4.Key Developments
19.5.5.Financial Analysis
19.5.6.SWOT Analysis
19.5.7.Business Strategies
19.6.Ilumina Inc
19.6.1.Company Details
19.6.2.Company Overview
19.6.3.Product Offerings
19.6.4.Key Developments
19.6.5.Financial Analysis
19.6.6.SWOT Analysis
19.6.7.Business Strategies
19.7.Indica Labs, Inc.
19.7.1.Company Details
19.7.2.Company Overview
19.7.3.Product Offerings
19.7.4.Key Developments
19.7.5.Financial Analysis
19.7.6.SWOT Analysis
19.7.7.Business Strategies
19.8.Miltenyi Biotec
19.8.1.Company Details
19.8.2.Company Overview
19.8.3.Product Offerings
19.8.4.Key Developments
19.8.5.Financial Analysis
19.8.6.SWOT Analysis
19.8.7.Business Strategies
19.9.NanoString Technologies Inc
19.9.1.Company Details
19.9.2.Company Overview
19.9.3.Product Offerings
19.9.4.Key Developments
19.9.5.Financial Analysis
19.9.6.SWOT Analysis
19.9.7.Business Strategies
19.10.Owkin
19.10.1.Company Details
19.10.2.Company Overview
19.10.3.Product Offerings
19.10.4.Key Developments
19.10.5.Financial Analysis
19.10.6.SWOT Analysis
19.10.7.Business Strategies
19.11.RareCyte, Inc.
19.11.1.Company Details
19.11.2.Company Overview
19.11.3.Product Offerings
19.11.4.Key Developments
19.11.5.Financial Analysis
19.11.6.SWOT Analysis
19.11.7.Business Strategies
19.12.S2 Genomics, Inc.
19.12.1.Company Details
19.12.2.Company Overview
19.12.3.Product Offerings
19.12.4.Key Developments
19.12.5.Financial Analysis
19.12.6.SWOT Analysis
19.12.7.Business Strategies
19.13.SciLifeLab
19.13.1.Company Details
19.13.2.Company Overview
19.13.3.Product Offerings
19.13.4.Key Developments
19.13.5.Financial Analysis
19.13.6.SWOT Analysis
19.13.7.Business Strategies
19.14.Ultivue Inc.
19.14.1.Company Details
19.14.2.Company Overview
19.14.3.Product Offerings
19.14.4.Key Developments
19.14.5.Financial Analysis
19.14.6.SWOT Analysis
19.14.7.Business Strategies
19.15.Visiopharm A/S
19.15.1.Company Details
19.15.2.Company Overview
19.15.3.Product Offerings
19.15.4.Key Developments
19.15.5.Financial Analysis
19.15.6.SWOT Analysis
19.15.7.Business Strategies
19.16.ZEISS
19.16.1.Company Details
19.16.2.Company Overview
19.16.3.Product Offerings
19.16.4.Key Developments
19.16.5.Financial Analysis
19.16.6.SWOT Analysis
19.16.7.Business Strategies
19.17.Other market participants
20.Key Findings

.

.

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

.

**Exclusive for Multi-User and Enterprise User.

.

Global Spatial OMICS Market Segmentation

By Techniques

 Spatial Transcriptomics
 Immunohistochemistry (IHC)

 Fluorescence In-Situ Hybridization (FISH)

 Sequencing
· In Situ Sequencing (ISS)

· Microdissection Sequencing

· Others

 In-Situ capturing

 Microscopy based RNA imaging techniques
· Padlock Probes & Rolling Circle Amplification

· Single Molecule RNS Fluorescence In-Situ Hybridization (smFISH)

· Branched DNA probes

 Transcriptome In-Vivo Analysis (TIVA)

 Spatial Genomics
 Fluorescence in situ Sequencing

 Fluorescence Microscopy-based

 Others

 Spatial proteomics

 Spatial metabolomics

 Spatial multi-omics

 Others

By Offerings

 Products

 Solutions

 Consumables

By Application

 Biomarker Discovery

 Drug Development

 Cancer Research

 Infectious Diseases

 Immunology

 Metabolic Studies

 Others

By Sample Type

 Frozen tissues

 FFPE tissues

By End Users

 Academic and Research Institutes

 Pharmaceutical and Biotechnology Companies

 Contract Research Organizations (CROs)

 Others

By Region

 North America (U.S., Canada, Mexico, Rest of North America)

 Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)

 Asia Pacific (China, Japan, India, New Zealand, A